ENGINEERED ALBUMIN BINDING POLYPEPTIDE

Technical field

The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present disclosure relates to albumin binding polypeptides which have a high resistance to enzymatic cleavage and the therapeutic use thereof.

Background

Serum albumin

Serum albumin is the most abundant protein in mammalian sera (35-50 g/l, i.e. 0.53-0.75 mM, in humans), and one of its functions is to bind molecules such as lipids and bilirubin (Peters T, Advances in Protein

Chemistry 37:161 , 1985). The half-life of serum albumin is directly

proportional to the size of the animal, where for example human serum albumin (HSA) has a half-life of 19 days and rabbit serum albumin has a half- life of about 5 days (McCurdy TR et al, J Lab Clin Med 143:1 15, 2004).

Human serum albumin is widely distributed throughout the body, in particular in the intestinal and blood compartments, where it is mainly involved in the maintenance of osmolarity. Structurally, albumins are single-chain proteins comprising three homologous domains and totaling 584 or 585 amino acids (Dugaiczyk L et al, Proc Natl Acad Sci USA 79:71 , 1982). Albumins contain 17 disulfide bridges and a single reactive thiol, C34, but lack N-linked and O- linked carbohydrate moieties (Peters, 1985, supra; Nicholson JP et al, Br J Anaesth 85:599, 2000). The lack of glycosylation simplifies recombinant expression of albumin. This property of albumin, together with the fact that its three-dimensional structure is known (He XM and Carter DC, Nature 358:209 1992), has made it an attractive candidate for use in recombinant fusion proteins. Such fusion proteins generally combine a therapeutic protein (which would be rapidly cleared from the body upon administration of the protein per se) and a plasma protein (which exhibits a natural slow clearance) in a single polypeptide chain (Sheffield WP, Curr Drug Targets Cardiovacs Haematol Disord 1 :1 , 2001 ). Such fusion proteins may provide clinical benefits in requiring less frequent injection and higher levels of therapeutic protein in vivo. Fusion or association with HSA results in increased in vivo half-life of proteins

Serum albumin is devoid of any enzymatic or immunological function and, thus, should not exhibit undesired side effects upon coupling to a bioactive polypeptide. Furthermore, HSA is a natural carrier involved in the endogenous transport and delivery of numerous natural as well as therapeutic molecules (Sellers EM and Koch-Weser MD, "Albumin Structure, Function and Uses", eds Rosenoer VM et al, Pergamon, Oxford, p 159, 1977). Several strategies have been reported to either covalently couple proteins directly to serum albumins or to a peptide or protein that will allow in vivo association to serum albumins. Examples of the latter approach have been described e.g. in WO91/01743. This document describes inter alia the use of albumin binding peptides or proteins derived from streptococcal protein G for increasing the half-life of other proteins. The idea is to fuse the bacterially derived, albumin binding peptide/protein to a therapeutically interesting peptide/protein, which has been shown to have a rapid clearance in blood. The thus generated fusion protein binds to serum albumin in vivo, and benefits from its longer half-life, which increases the net half-life of the fused therapeutically interesting peptide/protein. Association with HSA results in decreased immunogenicity

In addition to the effect on the in vivo half-life of a biologically active protein, it has been proposed that the non-covalent association with albumin of a fusion between a biologically active protein and an albumin binding protein acts to reduce the immune response to the biologically active protein. Thus, in WO2005/097202, there is described the use of this principle to reduce or eliminate the immune response to a biologically active protein.

Albumin binding domains of bacterial receptor proteins

Streptococcal protein G is a bi-functional receptor present on the surface of certain strains of streptococci and capable of binding to both IgG and serum albumin (Bjorck et al, Mol Immunol 24:1 1 13, 1987). The structure is highly repetitive with several structurally and functionally different domains (Guss et al, EMBO J 5:1567, 1986), more precisely three Ig-binding motifs and three serum albumin binding domains (Olsson et al, Eur J Biochem 168:319, 1987). The structure of one of the three serum albumin binding domains has been determined, showing a three-helix bundle domain (Kraulis et al, FEBS Lett 378:190, 1996). This motif was named ABD (albumin binding c/omain) and is 46 amino acid residues in size. In the literature, it has subsequently also been designated G148-GA3.

Other bacterial albumin binding proteins than protein G from

Streptococcus have also been identified, which contain domains similar to the albumin binding three-helix domains of protein G. Examples of such proteins are the PAB, PPL, MAG and ZAG proteins. Studies of structure and function of such albumin binding proteins have been carried out and reported e.g. by Johansson and co-workers (Johansson et al, J Mol Biol 266:859-865, 1997; Johansson et al, J Biol Chem 277:81 14-8120, 2002), who introduced the designation "GA module" (protein G-related albumin binding module) for the three-helix protein domain responsible for albumin binding. Furthermore, Rozak et al have reported on the creation of artificial variants of the GA module, which were selected and studied with regard to different species specificity and stability (Rozak et al, Biochemistry 45:3263-3271 , 2006; He et al, Protein Science 16:1490-1494, 2007). In the present disclosure, the terminology with regard to GA modules from different bacterial species established in the articles by Johansson et al and by Rozak et a/ will be followed.

Recently, variants of the G148-GA3 domain have been developed, with various optimized characteristics. Such variants are for example disclosed in PCT publications WO2009/016043, WO2012/004384 and WO2014/048977.

Oral delivery of protein therapeutics

The majority of protein and peptide therapeutics currently on the market are administered by the parenteral route, i.e. without passing the

gastrointestinal tract, such as by intravenous, intramuscular or subcutaneous injections. Intravenous administration directly into the systemic circulation provides 100 % bioavailability and fast onset of drug action. However, the instant high concentration of the drug in the blood increases the risk of side effects. Furthermore, administration by any injection method is associated with low patient compliance due to the pain and discomfort. Self- administration is often not possible and hence treatment has to be carried out in the clinic. The latter becomes a particular problem if the half-life of the drug is short, and frequent, repeated administrations are required to maintain adequate levels of therapeutic action. Clinical treatment, and in some cases necessary hospitalization of the patient, also implies increased costs for society. Simplified administration is thus a major driving force for development of drugs intended for alternative delivery routes such as oral, intranasal, pulmonary, transdermal or rectal, each of which is associated with specific advantages and limitations. Oral administration remains one of the most convenient administration routes, in particular for the treatment of pediatric patients. Furthermore, oral formulations do not require production under sterile conditions, which reduces the manufacturing costs per unit of drug (Salama et al, Adv Drug Deliv Rev. 58:15-28, 2006). For some protein therapeutics, the oral delivery route may even be more physiological, as has been suggested for insulin (Hoffman and Ziv, Clin Pharmacokinet. 33:285- 301 , 1997).

Oral delivery of conventional low molecular weight drugs has been well established in practice. However, oral delivery of larger, less stable and often polar, peptide and protein therapeutics faces other challenges including that the drug must 1 ) be resistant to the acidic environment of the stomach 2) be resistant to enzymatic degradation in the gastrointestinal tract and 3) be able to cross the intestinal epithelium and reach into the circulation. Different approaches have been attempted to address these challenges either by modifying the protein itself, or by optimizing the formulation or drug carrier system.

Factors influencing oral bioavailability

Bioavailability refers to the fraction of an administered dose of an active drug substance that reaches the systemic circulation. By definition, the bioavailability of an intravenously administered drug is 100 %. However, when the drug is administered via other routes, for instance by the oral route, the bioavailability decreases due to metabolism and incomplete absorbance.

The bioavailability of a protein therapeutic administered orally depends on the physiological properties of the protein, such as molecular weight, amino acid sequence, hydrophobicity, isoelectric point (pi), solubility and pH stability, as well as on the biological barriers encountered in the

gastrointestinal tract, i.e. the proteolytic environment and the generally poor absorption of large molecules through the intestinal wall.

The physiochemical environment of the gastrointestinal tract varies depending on the feeding status of the individual. Factors that vary between the fasted and fed stages include pH, the composition of gastrointestinal fluids and the volume of the stomach. In humans, the pH of the stomach is around 1 -2 in the fed state whereas it rises to 3-7 in the fasted state. The pH varies throughout the small intestine, but averages around pH 5 and 6.5 in the fed and fasted state, respectively (Klein, AAPS J.12:397-406, 2010). The differences in pH affect the level of activity of proteolytic enzymes, which are each associated with a specific pH optimum. Pepsin, the predominant protease in the stomach, has optimal activity around pH 2, whereas trypsin and chymotrypsin of the intestine has optimal activity around pH 8.

Furthermore, gastric emptying is a rate-limiting step. Food, in particular fatty food, slows gastric emptying and hence the rate of drug absorption (Singh, Clin Pharmacokinet. 37:213-55, 1999), and thus prolongs the time during which the drug is exposed to proteolytic enzymes. Therefore, the

bioavailability of the drug can be affected if the drug is taken during or in between meals, with or without a significant of volume liquid, or different types of liquid.

Poor absorption through the intestinal wall remains the main factor limiting the bioavailability of orally delivered protein therapeutics. Drugs taken orally have, as with any nutrient, two options to cross the intestinal wall; by using either the transcellular pathway, which involves passage across cells, or the paracellular pathway, which involves passage between adjacent cells via tight junctions. Molecules with a molecular weight of less than 500 Da can cross using either pathway (Muller, Curr Issues Mol Biol 13:13-24, 201 1 ). The ability of drugs with a larger molecular weight to cross the intestinal wall depends on the physiochemical properties of the drug, such as charge, lipophilicity and hydrophilicity. For lipophilic drugs, the transcellular route dominates, whereas hydrophilic drugs can cross by the paracellular route (Salama et al, 2006, supra). However, the dimension of the paracellular space is between 10 and 30-50 A, and it has been suggested that the paracellular transport is generally limited to molecules with a radius less than 15 A (-3.5 kDa) (Rubas et al, J Pharm Sci. 85:165-9, 1996). As for the transcellular pathway, substances with a small molecular weight readily cross by passive diffusion. However, substances having a larger molecular weight are confined to active processes requiring energy expenditure, such as pinocytocis (nonspecific "cell drinking") or transcytosis (receptor-mediated transport).

Finally, bioavailability is also influenced by interpatient variability, including age (drugs are generally metabolized more slowly in fetal, neonatal and geriatric populations), health of the gastrointestinal tract, and general disease state (e.g. hepatic insufficiency, poor renal function), as well as intrapatient variability, i.e. variability in the same patient over time.

Increasing the bioavailability of orally administered proteins and peptides is crucial for enabling delivery of a therapeutically effective dose, reducing the manufacturing costs and to a lesser extent reducing the effect of interpatient and intrapatient variability. Strategies to improve the oral bioavailability of protein therapeutics have ranged from changing physiochemical properties such as hydrophobicity, charge, pH stability and solubility; inclusion of protease inhibitors or absorbance enhancers in the drug formulation; and use of formulation vehicles such as emulsions, liposomes, microspheres or nanoparticles (reviewed in Park et al, Reactive and Functional Polymers, 71 :280-287, 201 1 ).

Protein engineering for increased in vivo stability

Small robust proteins can potentially be engineered to withstand the rough conditions in the gastrointestinal tract and be small enough to be absorbed into the bloodstream. Naturally occurring, stable proteins such as cyclotides and cysteine knot mini-proteins have been studied and engineered

(Craik et al, The Journal of Organic Chemistry, 76:4805, 201 1 and Werle et al, Journal of Drug Targeting 14:137, 2006). These naturally occurring proteins are cyclic, which is a feature also shared by the peptide hormones oxytocin and somatostatin.

Stabilization of peptides and proteins by the introduction of thioether bridges in proteins naturally devoid of an intra-molecular crosslink has been tested (Rink et al, Journal of Pharmacological and Toxicological Methods,

61 :210, 2010 and Kluskens et al, The Journal of Pharmacology and

Experimental Therapeutics, 328: 849, 2009).

In summary, considering the relatively low bioavailability of orally administered peptide and protein drugs, it is highly relevant to both reduce the amount that is degraded by gastrointestinal proteases and maintain a long in vivo plasma half-life of the fraction of the drug which crosses the intestinal epithelial membrane in a biologically active form. As is evident from the background description above, there is a need for the provision of therapeutically effective biopharmaceuticals which can for example be administered via the oral route. Disclosure of the invention

It is an object of the present disclosure to provide new albumin binding molecules, which could be used in therapeutic applications.

It is another object of the present disclosure to provide a molecule allowing for efficient therapy while alleviating the above mentioned and other drawbacks of current therapies.

It is furthermore an object of the present disclosure to provide a molecule suitable for oral delivery.

Another object of the present disclosure is to provide a molecule with a high resistance to proteolytic cleavage.

These and other objects, which are evident to the skilled person from the present disclosure, are met by different aspects of the invention as claimed in the appended claims and as generally disclosed herein.

In a first aspect, the disclosure provides an albumin binding polypeptide comprising an albumin binding motif [ABM], which motif consists of the amino acid sequence

GXASDXsYKXeXgl Xl iXi2 X-| ₄ TVEGVX20 ALX23X2 ₄ X2SILX28X29XB wherein, independently from each other,

XA is selected from C and K;

XB is selected from C and K; and

X ₅ is selected from F and Y;

X ₈ is selected from D, K, N, R and S;

X9 is selected from F, I, L, M, V and Y;

X11 is selected from D, E, N and S;

X12 is selected from K, N and R;

Xi ₄ is selected from K and R;

X ₂₀ is selected from D, E, H, K, N, Q, R and S;

X23 is selected from I, K and T;

X2 ₄ is selected from A, D, E, G, H, L, S and T; X25 is selected from A, D, E and H;

X28 is selected from A and K; and

X29 is selected from A, E and S. In one embodiment, X _A is C.

In another embodiment, X _A is K.

In one embodiment, X _B is C.

In another embodiment, X _B is K. In other words, XAXB is selected from CK, KC, CC and KK, for example selected from CK, KC and CC, such as selected from CK and CC. Thus, in one specific embodiment, X _A XB is CK. In another specific embodiment, X _A XB is CC. In yet another specific embodiment, XAXB is KC. In another specific embodiment, X _A XB is KK.

In order to provide albumin binding polypeptides which are suitable to therapeutic applications, such as albumin binding polypeptides that are suitable for oral delivery and exhibit high resistant to proteolytic cleavage, such as cleavage by gastrointestinal proteases for example pepsin, trypsin and chymotrypsin, the inventors have studied variants of PEP07830 (SEQ ID NO:1774). For example, the inventors show that a crosslink between residue XA, corresponding to position 2 in the above mentioned sequence, and residue XB, corresponding to position 30 in the above mentioned sequence, leads to an improved protease stability while albumin binding ability is retained, in contrast to other tested crosslinked variants (as described in Examples 4 and 5 below).

The albumin binding motif, or ABM, corresponds to the albumin binding region of the G148-GA3, which region constitutes two alpha helices within a three-helical bundle protein domain. It is known that the original amino acid residues of said two alpha helices in the parent scaffold constitute a binding surface for interaction with albumin.

As the skilled person will realize, the function of any polypeptide, such as the albumin binding capacity of the polypeptides according to the present disclosure, is dependent on the tertiary structure of said polypeptide. It is therefore generally possible to make minor changes to the sequence of amino acids in a polypeptide without affecting the function thereof. For example, it is possible that an amino acid residue belonging to a certain functional group of amino acid residues (e.g. hydrophobic, hydrophilic, polar etc) could be exchanged for another amino acid residue from the same functional group.

Thus, the present disclosure encompasses variants of originally described or naturally occurring albumin binding polypeptides, which are such that the albumin binding characteristics are retained. For example, the present disclosure encompasses modified variants of albumin binding polypeptides previously described in PCT publications WO2009/016043, WO2012/004384 and WO2014/048977; it is contemplated that the

modifications described herein make these previously described albumin binders more useful in the various applications referred to in the background section above. A skilled person would appreciate that said modifications are equally applicable to any albumin binding polypeptide based on the G148- GA3 scaffold, as such modifications do not alter the three dimensional conformation required for interaction with albumin.

Hence, the present disclosure encompasses ABMs comprising substitution mutations that do not significantly diminish albumin binding characteristics, while simultaneously confer improved properties upon said ABM which render it more useful for therapeutic applications, such as treatment via oral administration.

In one embodiment, X ₅ s F.

In one embodiment, X ₅ s Y.

In one embodiment, X ₈ s selected from K, N, R and S

In one embodiment, X ₈ s selected from N, R and S.

In one embodiment, X ₈ s selected from K, N and R.

In one embodiment, X ₈ s selected from N and R.

In one embodiment, X ₈ s selected from K and R.

In one embodiment, X ₈ s R.

In one embodiment, X ₈ s N.

In one embodiment, X ₈ s K.

In one embodiment, X ₉ s L.

In one embodiment, Xl 1 is selected from D, E and N.

In one embodiment, Xl 1 is selected from N and S.

In one embodiment, Xl 1 is N.

In one embodiment, Xl 1 is selected from D and E.

In one embodiment, Xl 1 is D. In one embod ment Xl 1 is E.

In one embod ment Xl2 is selected from K and N.

In one embod ment Xl2 is selected from K and R.

In one embod ment Xl2 is K.

In one embod ment Xl2 is N.

In one embod ment Xl2 is R.

In one embod ment Xl4 is K.

In one embod ment X20 is selected from D, E, H, N, Q R and S

In one embod ment X20 is selected from K and E.

In one embod ment X20 is E.

In one embod ment X20 is K.

In one embod ment X23 is selected from I and K.

In one embod ment X23 is I.

In one embod ment X23 is K.

In one embod ment X24 is selected from A, D, G, H, L, S and T.

In one embod ment X24 is selected from A, E, G, H, L, S and T.

In one embod ment X24 is selected from A, G, H, L, S and T.

In one embod ment X24 is selected from D, E and L

In one embod ment X24 is selected from D and E.

In one embod ment X24 is L.

In one embod ment X24 is D.

In one embod ment X24 is E.

In one embod ment X25 is selected from A, E and H

In one embod ment X25 is selected from A and H.

In one embod ment X25 is selected from A and E.

In one embod ment X25 is selected from D, E and H

In one embod ment X25 is selected from D and E.

In one embod ment X25 is E.

In one embod ment X25 is A.

In one embod ment X25 is D.

In one embod ment X25 is H.

In one embod ment X28 is A.

In one embod ment X29 is selected from A and S.

In one embod ment X29 is A.

In one embod ment X29 is S. In one embodiment, the ABM comprises an additional position X ₃ i located on the C-terminal side of the core sequence disclosed above. In one embodiment, the amino acid residue at position X ₃ i is P. As stated above, the substitution mutations designated XA and XB may be introduced into the sequences of albumin binding polypeptides previously described in PCT publications WO2009/016043, WO2012/004384 and WO2014/048977. Taking the disclosure in these PCT applications of individual albumin binding motifs into account, and considering the

experimental proof of correct functioning given in the experimental section to follow, the skilled person is in a position to visualize a substantial number of individual albumin binding motif (ABM) sequences. These sequences comprise the "crossl inking mutations" in positions XA and XB and constitute individual embodiments of the ABM sequence in the definition of albumin binding polypeptides according to this aspect of the present disclosure. The sequences of individual albumin binding polypeptides, from which individual albumin binding motifs may be deduced, are presented in Figure 1 and denoted SEQ ID NO:1 -1768.

Thus, in one embodiment of the albumin binding polypeptide according to the invention, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1 -1768.

In one embodiment, X _A is C and XB is C or K, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1 , 3, 5, 7, 9, 1 1 , 13, 15, 17, 19, 21 , 23, 25, 27, 29, 31 , 33, 35, 37, 39, 41 , 43, 45, 47, 49, 51 , 53, 55, 57, 59, 61 , 63, 65, 67, 69, 71 , 73, 75, 77, 79, 81 , 83, 85, 87, 89, 91 , 93, 95, 97, 99, 101 , 103, 105, 107, 109, 1 1 1 , 1 13, 1 15, 1 17, 1 19, 121 , 123, 125, 127, 129, 131 , 133, 135, 137, 139, 141 , 143, 145, 147, 149, 151 , 153, 155, 157, 159, 161 , 163, 165, 167, 169, 171 , 173, 175, 177, 179, 181 , 183, 185, 187, 189, 191 , 193, 195, 197, 199, 201 , 203, 205, 207, 209, 21 1 , 213, 215, 217, 219, 221 , 223, 225, 227, 229, 231 , 233, 235, 237, 239, 241 , 243, 245, 247, 249, 251 , 253, 255, 257, 259, 261 , 263, 265, 267, 269, 271 , 273, 275, 277, 279, 281 , 283, 285, 287, 289, 291 , 293, 295, 297, 299, 301 , 303, 305, 307, 309, 31 1 , 313, 315, 317, 319, 321 , 323, 325, 327, 329, 331 , 333, 335, 337, 339, 341 , 343, 345, 347, 349, 351 , 353, 355, 357, 359, 361 , 363, 365, 367, 369, 371 , 373, 375, 377, 379, 381 , 383, 385, 387, 389, 391 , 393, 395, 397, 399, 401 403 405 407 409 411 413,415,417,419, 421

423, 425, 427, 429, 431 433 435 437 439 441 443, 445, 447, 449, 451

453, 455, 457, 459, 461 463 465 467 469 471 473, 475, 477, 479, 481

483, 485, 487, 489, 491 493 495 497 499 501 503, 505, 507, 509, 511

513, 515, 517, 519, 521 523 525 527 529 531 533, 535, 537, 539, 541

543, 545, 547, 549, 551 553 555 557 559 561 563, 565, 567, 569, 571

573, 575, 577, 579, 581 583 585 587 589 591 593, 595, 597, 599, 601

603, 605, 607, 609, 611 613 615 617 619 621 623, 625, 627, 629, 631

633, 635, 637, 639, 641 643 645 647 649 651 653, 655, 657, 659, 661

663, 665, 667, 669, 671 673 675 677 679 681 683, 685, 687, 689, 691

693, 695, 697, 699, 701 703 705 707 709 711 713, 715, 717, 719, 721

723, 725, 727, 729, 731 733 735 737 739 741 743, 745, 747, 749, 751

753, 755, 757, 759, 761 763 765 767 769 771 773, 775, 777, 779, 781

783, 785, 787, 789, 791 793 795 797 799 801 803, 805, 807, 809, 811

813, 815, 817, 819, 821 823 825 827 829 831 833, 835, 837, 839, 841

843, 845, 847, 849, 851 853 855 857 859 861 863, 865, 867, 869, 871

873, 875, 877, 879, 881 883 885 887 889 891 893, 895, 897, 899, 901

903, 905, 907, 909, 911 913 915 917 919 921 923, 925, 927, 929, 931

933, 935, 937, 939, 941 943 945 947 949 951 953, 955, 957, 959, 961

963, 965, 967, 969, 971 973 975 977 979 981 983, 985, 987, 989, 991

993, 995, 997, 999, 1001 , 1003, 1005, 1007 1 009 , 1011, 1013, 1015, 101

1019, 1021, 1023, 1 025 1027, 1029, 1031, 1 033 1035, 1037, 1039, 1041

1043, 1045, 1047, 1 049 1051, 1053, 1055, 1057 1059, 1061, 1063, 1065

1067, 1069, 1071, 1 073 1075, 1077, 1079, 1081 1083, 1085, 1087, 1089

1091, 1093, 1095, 1 097 1099, 1101, 1103, 1105 1107, 1109, 1111, 1113

1115, 1117, 1119, 1 121 1123, 1125, 1127, 1129 1131, 1133, 1135, 1137

1139, 1141, 1143, 1 145 1147, 1149, 1151, 1153 1155, 1157, 1159, 1161

1163, 1165, 1167, 1 169 1171, 1173, 1175, 1177 1179, 1181, 1183, 1185

1187, 1189, 1191, 1 193 1195, 1197, 1199, 1201 1203, 1205, 1207, 1209

1211, 1213, 1215, 1 217 1219, 1221, 1223, 1225 1227, 1229, 1231, 1233

1235, 1237, 1239, 1 241 1243, 1245, 1247, 1249 1251, 1253, 1255, 1257

1259, 1261, 1263, 1 265 1267, 1269, 1271, 1273 1275, 1277, 1279, 1281

1283, 1285, 1287, 1 289 1291, 1293, 1295, 1297 1299, 1301, 1303, 1305

1307, 1309, 1311, 1 313 1315, 1317, 1319, 1321 1323, 1325, 1327, 1329

1331, 1333, 1335, 1 337 1339, 1341, 1343, 1345 1347, 1349, 1351, 1353

1355, 1357, 1359, 1 361 1363, 1365, 1367, 1369 1371, 1373, 1375, 1377

1379, 1381, 1383, 1 385 1387, 1389, 1391, 1393 1395, 1397, 1399, 1401 1403, 1405, 1407, 1409, 1411, 1413, 1415, 1417, 1419, 1421, 1423, 1425, 1427, 1429, 1431, 1433, 1435, 1437, 1439, 1441, 1443, 1445, 1447, 1449, 1451, 1453, 1455, 1457, 1459, 1461, 1463, 1465, 1467, 1469, 1471, 1473, 1475, 1477, 1479, 1481, 1483, 1485, 1487, 1489, 1491, 1493, 1495, 1497, 1499, 1501, 1503, 1505, 1507, 1509, 1511, 1513, 1515, 1517, 1519, 1521, 1523, 1525, 1527, 1529, 1531, 1533, 1535, 1537, 1539, 1541, 1543, 1545, 1547, 1549, 1551, 1553, 1555, 1557, 1559, 1561, 1563, 1565, 1567, 1569, 1571, 1573, 1575, 1577, 1579, 1581, 1583, 1585, 1587, 1589, 1591, 1593, 1595, 1597, 1599, 1601, 1603, 1605, 1607, 1609, 1611, 1613, 1615, 1617, 1619, 1621 , 1623, 1625, 1627, 1629, 1631 , 1633, 1635, 1637, 1639, 1641 , 1643, 1645, 1647, 1649, 1651, 1653, 1655, 1657, 1659, 1661, 1663, 1665, 1667, 1669, 1671, 1673, 1675, 1677, 1679, 1681, 1683, 1685, 1687, 1689, 1691, 1693, 1695, 1697, 1699, 1701, 1703, 1705, 1707, 1709, 1711, 1713, 1715, 1717, 1719, 1721, 1723, 1725, 1727, 1729, 1731, 1733, 1735, 1737, 1739, 1741 , 1743, 1745, 1747, 1749, 1751 , 1753, 1755, 1757, 1759, 1761 , 1763, 1765 and 1767.

In another embodiment, X _A is C and XB is K, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1, 5, 9, 13, 17, 21 , 25, 29, 33, 37, 41 , 45, 49, 53, 57, 61 , 65, 69, 73, 77, 81 , 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129, 133, 137, 141, 145, 149, 153,

157, 161, 165, 169, 173, 177, 181, 185, 189, 193, 197, 201, 205, 209, 213

217, 221, 225, 229, 233, 237, 241, 245, 249, 253, 257, 261, 265, 269, 273

277, 281, 285, 289, 293, 297, 301, 305, 309, 313, 317, 321, 325, 329, 333

337, 341, 345, 349, 353, 357, 361, 365, 369, 373, 377, 381, 385, 389, 393

397, 401, 405, 409, 413, 417, 421, 425, 429, 433, 437, 441, 445, 449, 453

457, 461, 465, 469, 473, 477, 481, 485, 489, 493, 497, 501, 505, 509, 513

517, 521, 525, 529, 533, 537, 541, 545, 549, 553, 557, 561, 565, 569, 573

577, 581, 585, 589, 593, 597, 601, 605, 609, 613, 617, 621, 625, 629, 633

637, 641, 645, 649, 653, 657, 661 665, 669, 673, 677, 681 685, 689, 693

697, 701, 705, 709, 713, 717, 721, 725, 729, 733, 737, 741, 745, 749, 753

757, 761, 765, 769, 773, 777, 781, 785, 789, 793, 797, 801, 805, 809, 813

817, 821, 825, 829, 833, 837, 841, 845, 849, 853, 857, 861, 865, 869, 873

877, 881, 885, 889, 893, 897, 901, 905, 909, 913, 917, 921, 925, 929, 933

937, 941, 945, 949, 953, 957, 961, 965, 969, 973, 977, 981, 985, 989, 993

997, 1001, 1005, 1009, 1013, 1017, 1021, 1025, 1029, 1033, 1037, 1041, 1045, 1049, 1053, 1057, 1061, 1065, 1069, 1073, 1077, 1081, 1085, 1089, 1093, 1097, 1101, 1105, 1109, 1113, 1117, 1121, 1125, 1129, 1133, 1137, 1141, 1145, 1149, 1153, 1157, 1161, 1165, 1169, 1173, 1177, 1181, 1185, 1189, 1193, 1197, 1201, 1205, 1209, 1213, 1217, 1221, 1225, 1229, 1233, 1237, 1241, 1245, 1249, 1253, 1257, 1261, 1265, 1269, 1273, 1277, 1281, 1285, 1289, 1293, 1297, 1301 , 1305, 1309, 1313, 1317, 1321 , 1325, 1329, 1333, 1337, 1341, 1345, 1349, 1353, 1357, 1361, 1365, 1369, 1373, 1377, 1381, 1385, 1389, 1393, 1397, 1401, 1405, 1409, 1413, 1417, 1421, 1425, 1429, 1433, 1437, 1441, 1445, 1449, 1453, 1457, 1461, 1465, 1469, 1473, 1477, 1481, 1485, 1489, 1493, 1497, 1501, 1505, 1509, 1513, 1517, 1521, 1525, 1529, 1533, 1537, 1541 , 1545, 1549, 1553, 1557, 1561 , 1565, 1569, 1573, 1577, 1581, 1585, 1589, 1593, 1597, 1601, 1605, 1609, 1613, 1617, 1621, 1625, 1629, 1633, 1637, 1641, 1645, 1649, 1653, 1657, 1661, 1665, 1669, 1673, 1677, 1681, 1685, 1689, 1693, 1697, 1701, 1705, 1709, 1713, 1717, 1721, 1725, 1729, 1733, 1737, 1741, 1745, 1749, 1753, 1757, 1761 and 1765.

In another embodiment, the ABM sequence is one of the sequences listed in PCT publication WO2009/016043, mutated as described herein through substitution in the XA and XB positions. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:5-1004.

In another embodiment, X _A is C and XB is C or K in these sequences from WO2009/016043, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:5, 7, 9, 11 , 13, 15, 17, 19, 21 , 23, 25, 27, 29, 31 , 33, 35, 37, 39, 41 , 43, 45, 47, 49, 51 , 53, 55, 57, 59, 61 , 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211, 213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 241, 243, 245, 247, 249, 251, 253, 255, 257, 259, 261, 263, 265, 267, 269, 271, 273, 275, 277, 279, 281, 283, 285, 287, 289, 291 , 293, 295, 297, 299, 301 , 303, 305, 307, 309, 311,313, 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361, 363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391, 393, 395, 397, 399, 401, 403,

405, 407, 409, 411, 413, 415, 417, 419, 421, 423, 425, 427, 429, 431, 433,

435, 437, 439, 441, 443, 445, 447, 449, 451, 453, 455, 457, 459, 461, 463,

465, 467, 469, 471 473, 475, 477, 479, 481 483, 485, 487, 489, 491 493,

495, 497, 499, 501, 503, 505, 507, 509, 511, 513, 515, 517, 519, 521, 523,

525, 527, 529, 531, 533, 535, 537, 539, 541, 543, 545, 547, 549, 551, 553,

555, 557, 559, 561, 563, 565, 567, 569, 571, 573, 575, 577, 579, 581 583,

585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613,

615, 617, 619, 621, 623, 625, 627, 629, 631, 633, 635, 637, 639, 641, 643,

645, 647, 649, 651, 653, 655, 657, 659, 661, 663, 665, 667, 669, 671, 673,

675, 677, 679, 681 683, 685, 687, 689, 691 693, 695, 697, 699, 701 703,

705, 707, 709, 711, 713, 715, 717, 719, 721, 723, 725, 727, 729, 731, 733,

735, 737, 739, 741, 743, 745, 747, 749, 751, 753, 755, 757, 759, 761, 763,

765, 767, 769, 771, 773, 775, 777, 779, 781 783, 785, 787, 789, 791 793,

795, 797, 799, 801, 803, 805, 807, 809, 811, 813, 815, 817, 819, 821, 823,

825, 827, 829, 831, 833, 835, 837, 839, 841, 843, 845, 847, 849, 851, 853,

855, 857, 859, 861, 863, 865, 867, 869, 871, 873, 875, 877, 879, 881, 883,

885, 887, 889, 891, 893, 895, 897, 899, 901, 903, 905, 907, 909, 911, 913,

915, 917, 919, 921, 923, 925, 927, 929, 931, 933, 935, 937, 939, 941, 943,

945, 947, 949, 951, 953, 955, 957, 959, 961, 963, 965, 967, 969, 971, 973,

975, 977, 979, 981, 983, 985, 987, 989, 991 993, 995, 997, 999, 1001 and

1003.

In another embodiment, X _A is C and XB is K in these sequences from WO2009/016043, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 49, 53, 57, 61 , 65, 69, 73, 77, 81 , 85, 89, 93, 97, 101 , 105, 109, 113, 117, 121 , 125,

129, 133, 137, 141, 145, 149, 153, 157, 161, 165, 169, 173, 177, 181, 185

189, 193, 197, 201, 205, 209, 213, 217, 221, 225, 229, 233, 237, 241, 245

249, 253, 257, 261, 265, 269, 273, 277, 281, 285, 289, 293, 297, 301, 305

309, 313, 317, 321, 325, 329, 333, 337, 341, 345, 349, 353, 357, 361, 365

369, 373, 377, 381, 385, 389, 393, 397, 401, 405, 409, 413, 417, 421 425

429, 433, 437, 441, 445, 449, 453, 457, 461, 465, 469, 473, 477, 481, 485

489, 493, 497, 501, 505, 509, 513, 517, 521, 525, 529, 533, 537, 541, 545

549, 553, 557, 561, 565, 569, 573, 577, 581, 585, 589, 593, 597, 601, 605

609, 613, 617, 621, 625, 629, 633, 637, 641, 645, 649, 653, 657, 661, 665

669, 673, 677, 681, 685, 689, 693, 697, 701, 705, 709, 713, 717, 721, 725 729, 733, 737, 741 , 745, 749, 753, 757, 761 , 765, 769, 773, 777, 781 , 785, 789, 793, 797, 801 , 805, 809, 813, 817, 821 , 825, 829, 833, 837, 841 , 845, 849, 853, 857, 861 , 865, 869, 873, 877, 881 , 885, 889, 893, 897, 901 , 905, 909, 913, 917, 921 , 925, 929, 933, 937, 941 , 945, 949, 953, 957, 961 , 965, 969, 973, 977, 981 , 985, 989, 993, 997 and 1001 .

In another embodiment, the ABM sequence is a mutated version of any one of the albumin binding motif sequences disclosed in claim 24 of

WO2009/016043. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:9-12, 13-16, 37- 40, 61 -64, 101 -104, 109-1 12, 185-188, 197-200, 213-216, 217-220, 221 -224, 617-620, 925-928, 929-932, 933-936, 937-940, 941 -944, 945-948 and 949- 952.

In another embodiment, X _A is C and XB is C or K in these sequences from claim 24 of WO2009/016043, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO: 9, 1 1 , 13, 15, 37, 39, 61 , 63, 101 , 103, 109, 1 1 1 , 185, 187, 197, 199, 213, 215, 217, 219, 221 , 223, 617, 619, 925, 927, 929, 931 , 933, 935, 937, 939, 941 , 943, 945, 947, 949 and 951 .

In another embodiment, X _A is C and XB is K in these sequences from claim 24 of WO2009/016043, so the ABM consists of an amino acid

sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:9, 13, 37, 61 , 101 , 109, 185, 197, 213, 217, 221 , 617, 925, 929, 933, 937, 941 , 945 and 949.

In another embodiment, the ABM sequence is a mutated version of any one of the albumin binding motif sequences disclosed in claim 25 of

WO2009/016043. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:9-12, 213-216 and 925-928.

In another embodiment, X _A is C and XB is C or K in these sequences from claim 25 of WO2009/016043, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:9, 11, 213, 215, 925 and 927.

In another embodiment, X _A is C and XB is K in these sequences from claim 25 of WO2009/016043, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:9, 213 and 925, such as SEQ ID NO:925.

In another embodiment, the ABM sequence is one of the sequences listed in PCT publication WO2012/004384, mutated as described herein through substitution in the XA and XB positions. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1-4 and 1005-1736. In another embodiment, the ABM sequence consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from SEQ ID NO:1-4.

In another embodiment, X _A is C and XB is C or K in these sequences from WO2012/004384, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, 1023, 1025, 1027, 1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043, 1045, 1047, 1049, 1051, 1053, 1055, 1057, 1059, 1061, 1063, 1065, 1067, 1069, 1071, 1073, 1075, 1077, 1079, 1081, 1083, 1085, 1087, 1089, 1091, 1093, 1095, 1097, 1099, 1101, 1103, 1105, 1107, 1109, 1111, 1113, 1115, 1117, 1119, 1121, 1123, 1125, 1127, 1129, 1131, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147, 1149, 1151, 1153, 1155, 1157, 1159, 1161, 1163, 1165, 1167, 1169, 1171, 1173, 1175, 1177, 1179, 1181, 1183, 1185, 1187, 1189, 1191, 1193, 1195, 1197, 1199, 1201, 1203, 1205, 1207, 1209, 1211, 1213, 1215, 1217, 1219, 1221, 1223, 1225, 1227, 1229, 1231 , 1233, 1235, 1237, 1239, 1241 , 1243, 1245, 1247, 1249, 1251 , 1253, 1255, 1257, 1259, 1261, 1263, 1265, 1267, 1269, 1271, 1273, 1275, 1277, 1279, 1281, 1283, 1285, 1287, 1289, 1291, 1293, 1295, 1297, 1299, 1301, 1303, 1305, 1307, 1309, 1311, 1313, 1315, 1317, 1319, 1321, 1323, 1325, 1327, 1329, 1331, 1333, 1335, 1337, 1339, 1341, 1343, 1345, 1347, 1349, 1351 , 1353, 1355, 1357, 1359, 1361 , 1363, 1365, 1367, 1369, 1371 , 1373, 1375, 1377, 1379, 1381, 1383, 1385, 1387, 1389, 1391, 1393, 1395, 1397, 1399, 1401, 1403, 1405, 1407, 1409, 1411, 1413, 1415, 1417, 1419, 1421, 1423, 1425, 1427, 1429, 1431, 1433, 1435, 1437, 1439, 1441, 1443, 1445

1447, 1449, 1451, 1453, 1455, 1457, 1459, 1461, 1463, 1465, 1467, 1469

1471, 1473, 1475, 1477, 1479, 1481, 1483, 1485, 1487, 1489, 1491, 1493

1495, 1497, 1499, 1501, 1503, 1505, 1507, 1509, 1511, 1513, 1515, 1517

1519, 1521, 1523, 1525, 1527, 1529, 1531, 1533, 1535, 1537, 1539, 1541

1543, 1545, 1547, 1549, 1551, 1553, 1555, 1557, 1559, 1561, 1563, 1565

1567, 1569, 1571, 1573, 1575, 1577, 1579, 1581, 1583, 1585, 1587, 1589

1591, 1593, 1595, 1597, 1599, 1601, 1603, 1605, 1607, 1609, 1611, 1613

1615, 1617, 1619, 1621, 1623, 1625, 1627, 1629, 1631, 1633, 1635, 1637

1639, 1641, 1643, 1645, 1647, 1649, 1651, 1653, 1655, 1657, 1659, 1661

1663, 1665, 1667, 1669, 1671, 1673, 1675, 1677, 1679, 1681, 1683, 1685

1687, 1689, 1691, 1693, 1695, 1697, 1699, 1701, 1703, 1705, 1707, 1709

1711, 1713, 1715, 1717, 1719, 1721, 1723, 1725, 1727, 1729, 1731, 1733 and 1735.

In another embodiment, X _A is C and XB is K in these sequences from

WO2012/004384, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1 , 1005, 1009, 1013, 1017, 1021 , 1025, 1029,

1033, 1037, 1041, 1045, 1049, 1053, 1057, 1061, 1065, 1069, 1073, 1077

1081, 1085, 1089, 1093, 1097, 1101, 1105, 1109, 1113, 1117, 1121, 1125

1129, 1133, 1137, 1141, 1145, 1149, 1153, 1157, 1161, 1165, 1169, 1173

1177, 1181, 1185, 1189, 1193, 1197, 1201, 1205, 1209, 1213, 1217, 1221

1225, 1229, 1233, 1237, 1241, 1245, 1249, 1253, 1257, 1261, 1265, 1269

1273, 1277, 1281, 1285, 1289, 1293, 1297, 1301, 1305, 1309, 1313, 1317

1321, 1325, 1329, 1333, 1337, 1341, 1345, 1349, 1353, 1357, 1361, 1365

1369, 1373, 1377, 1381, 1385, 1389, 1393, 1397, 1401, 1405, 1409, 1413

1417, 1421, 1425, 1429, 1433, 1437, 1441, 1445, 1449, 1453, 1457, 1461

1465, 1469, 1473, 1477, 1481, 1485, 1489, 1493, 1497, 1501, 1505, 1509

1513, 1517, 1521, 1525, 1529, 1533, 1537, 1541, 1545, 1549, 1553, 1557

1561, 1565, 1569, 1573, 1577, 1581, 1585, 1589, 1593, 1597, 1601, 1605

1609, 1613, 1617, 1621, 1625, 1629, 1633, 1637, 1641, 1645, 1649, 1653

1657, 1661, 1665, 1669, 1673, 1677, 1681, 1685, 1689, 1693, 1697, 1701

1705, 1709, 1713, 1717, 1721, 1725, 1729 and 1733.

In another embodiment, the ABM sequence is a mutated version of the albumin binding motif in any one of the amino acid sequences disclosed in claim 23 of WO2012/004384. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1-4, 1017-1020, 1021-1024, 1029-1032, 1033-1036, 1041-1044, 1045-1048, 1053-1056, 1061-1064, 1065-1068, 1073-1076, 1077-1080, 1085-1088, 1089-1092, 1097-1100, 1101-1104, 1109-1112, 1113-1116, 1121-1124, 1125-1128, 1133-1136, 1137-1140, 1145-1148, 1149-1152, 1161-1164, 1165-1168, 1193-1196, 1197-1200, 1577-1580, 1581-1584, 1585-1588, 1589-1592, 1593-1596, 1597-1600, 1601-1604, 1689-1692, 1693-1696, 1697-1700, 1701-1704, 1705-1708, 1709-1712, 1713-1716, 1717-1720, 1721 -1724, 1725-1728, 1729-1732 and 1733-1736.

In another embodiment, X _A is C and XB is C or K in these sequences from claim 23 of WO2012/004384, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 1017, 1019, 1021 , 1023, 1029, 1031 , 1033, 1035, 1041 , 1043, 1045, 1047, 1053, 1055, 1061, 1063, 1065, 1067, 1073, 1075, 1077, 1079, 1085, 1087, 1089, 1091, 1097, 1099, 1101, 1103, 1109, 1111, 1113, 1115, 1121, 1123, 1125, 1127, 1133, 1135, 1137, 1139, 1145, 1147, 1149, 1151, 1161, 1163, 1165, 1167, 1193, 1195, 1197, 1199, 1577, 1579, 1581, 1583, 1585, 1587, 1589, 1591, 1593, 1595, 1597, 1599, 1601 , 1603, 1689, 1691 , 1693, 1695, 1697, 1699, 1701, 1703, 1705, 1707, 1709, 1711, 1713, 1715, 1717, 1719, 1721, 1723, 1725, 1727, 1729, 1731, 1733 and 1735.

In another embodiment, X _A is C and XB is K in these sequences from claim 23 of WO2012/004384, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting ofSEQIDNO:1, 1017, 1021, 1029, 1033, 1041, 1045, 1053, 1061, 1065, 1073, 1077, 1085, 1089, 1097, 1101, 1109, 1113, 1121, 1125, 1133, 1137, 1145, 1149, 1161, 1165, 1193, 1197, 1577, 1581, 1585, 1589, 1593, 1597, 1601, 1689, 1693, 1697, 1701, 1705, 1709, 1713, 1717, 1721 , 1725, 1729 and 1733.

In another embodiment, the ABM sequence is one of the sequences listed in PCT publication WO2014/048977, mutated as described herein through substitution in the XA and XB positions. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1737-1768. In another embodiment, X _A is C and XB is C or K in these sequences from PCT publication WO2014/048977, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO: 1737, 1739, 1741 , 1743, 1745, 1747, 1749, 1751 , 1753, 1755, 1757, 1759, 1761 , 1763, 1765 and 1767.

In another embodiment, X _A is C and XB is K in these sequences from PCT publication WO2014/048977, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO: 1737, 1741 , 1745, 1749, 1753, 1757, 1761 and 1765.

In another embodiment, the ABM sequence is a mutated version of the albumin binding motif sequence disclosed in claim 2 of PCT publication WO2014/048977. Thus, in this embodiment, the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1737-1740.

In another embodiment, X _A is C and XB is C or K in this sequence from claim 2 of PCT publication WO2014/048977, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO: 1737 and 1739.

In another embodiment, X _A is C and XB is K in this sequence from claim 2 of PCT publication WO2014/048977, so the ABM consists of an amino acid sequence extending from position 16 to position 45 in SEQ ID NO:1737.

In embodiments of the present disclosure, the ABM forms part of a three-helix bundle protein domain. For example, the ABM may essentially constitute, or form part of, two alpha helices with an interconnecting loop, within said three-helix bundle protein domain.

In particular embodiments, the three-helix bundle protein domain is selected from the group consisting of three-helix domains of bacterial receptor proteins. Non-limiting examples of such bacterial receptor proteins are selected from the group consisting of albumin binding receptor proteins from species of Streptococcus, Peptostreptococcus and Finegoldia, such as for example selected from the group consisting of proteins G, MAG, ZAG, PPL and PAB. In a specific embodiment, the ABM forms part of protein G, such as for example protein G from Streptococcus strain G148. In different variants of this embodiment, the three-helix bundle protein domain of which the ABM forms a part is selected from the group consisting of domain GA1 , domain GA2 and domain GA3 of protein G from Streptococcus strain G148, in particular domain GA3.

In alternative embodiments, the ABM forms part of one or more of the five three-helix domains of the bacterial receptor protein A from

Staphylococcus aureus; i.e. the three-helix bundle protein domain is selected from the group consisting of protein A domains A, B, C, D and E. In other similar embodiments, the ABM forms part of protein Z, derived from domain B of protein A from Staphylococcus aureus.

In embodiments of the present aspect wherein the ABM "forms part of a three-helix bundle protein domain, this is understood to mean that the sequence of the ABM is "inserted" into or "grafted" onto the sequence of the naturally occurring (or otherwise original) three-helix bundle domain, such that the ABM replaces a similar structural motif in the original domain. For example, without wishing to be bound by theory, the ABM is thought to constitute two of the three helices of a three-helix bundle, and can therefore replace such a two-helix motif within any three-helix bundle. As the skilled person will realize, the replacement of two helices of the three-helix bundle domain by the two ABM helices has to be performed so as not to affect the basic structure of the polypeptide. That is, the overall folding of the

Ca-backbone of the polypeptide according to this embodiment will be substantially the same as that of the three-helix bundle protein domain of which it forms a part, e.g. having the same elements of secondary structure in the same order etc. Thus, an ABM according to the present disclosure "forms part" of a three-helix bundle domain if the polypeptide according to this embodiment has the same fold as the original domain, implying that the basic structural properties are shared, those properties e.g. resulting in similar CD spectra. The skilled person is aware of other parameters that are relevant.

In one embodiment according to the first aspect of the present disclosure, the albumin binding polypeptide is a three-helix bundle protein domain, which comprises the ABM as defined above and additional sequences making up the remainder of the three-helix configuration. Thus, the present disclosure provides an albumin binding polypeptide, which comprises the amino acid sequence: LAXaAKXbXcAXdXe ELX _f X _g Y-[ABM] wherein

[ABM] is an albumin binding motif as defined herein, and, independently of each other,

X _a is selected from C, E, Q and S;

Xb is selected from C, E, S and V;

X _c is selected from A, D, E, L and S;

Xd is selected from I, N and L;

X _e is selected from A, K, R and S;

X _f is selected from D and K; and

X _g is selected from A, C, K and S.

In one embod ment X _a is selected from S and E.

In one embod ment X _a is S.

In one embod ment X _a is E.

In one embod ment Xb is selected from C, E and S.

In one embod ment Xb is selected from E and V.

In one embod ment X _b is E.

In one embod ment X _b is V.

In one embod ment Xc is selected from A and L.

In one embod ment Xc is selected from A and S.

In one embod ment Xc is A.

In one embod ment Xc is L.

In one embod ment X _d is N.

In one embod ment X _e is selected from A and R.

In one embod ment X _e is selected from A and S.

In one embod ment X _e is A.

In one embod ment X _e is R.

In one embod ment X _e is S.

In one embod ment X _f is D.

In one embod ment X _g is selected from C, K and S.

In one embod ment X _g is selected from K and S.

In one embod ment X _g is selected from C and S.

In one embod ment X _g is S. In one embodiment, X _g is K

In one embodiment, X _g is C

Once again, the substitution mutations designated XA and XB may be introduced into the sequences of albumin binding polypeptides previously described in PCT publications WO2009/016043, WO2012/004384 and WO2014/048977. In other words, the skilled person may visualize a substantial number of individual albumin binding polypeptides, in which the albumin binding motif as described herein forms a part. These sequences constitute individual embodiments of albumin binding polypeptides according to this aspect. As stated previously, the sequences of individual albumin binding polypeptides are presented in Figure 1 and denoted SEQ ID NO:1- 1768.

Thus, in one embodiment of the albumin binding polypeptide according to the disclosure, it comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-1768.

In one embodiment, X _A is C and XB is C or K, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29,

31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51 , 53, 55, 57, 59, 61, 63, 65, 67, 69,

71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91 , 93, 95, 97, 99, 101 , 103, 105, 107

109, 111, 113, 115, 117, 119, 121 , 123, 125, 127, 129, 131, 133, 135, 137,

139, 141, 143, 145, 147, 149, 151 , 153, 155, 157, 159, 161, 163, 165, 167,

169, 171, 173, 175, 177, 179, 181 , 183, 185, 187, 189, 191, 193, 195, 197,

199, 201, 203, 205, 207, 209, 211 , 213, 215, 217, 219, 221, 223, 225, 227,

229, 231, 233, 235, 237, 239, 241 , 243, 245, 247, 249, 251, 253, 255, 257,

259, 261, 263, 265, 267, 269, 271 , 273, 275, 277, 279, 281, 283, 285, 287,

289, 291, 293, 295, 297, 299, 301 , 303, 305, 307, 309, 311, 313, 315, 317,

319, 321, 323, 325, 327, 329, 331 , 333, 335, 337, 339, 341, 343, 345, 347,

349, 351, 353, 355, 357, 359, 361 , 363, 365, 367, 369, 371, 373, 375, 377,

379, 381, 383, 385, 387, 389, 391 , 393, 395, 397, 399, 401, 403, 405, 407,

409, 411, 413, 415, 417, 419, 421 , 423, 425, 427, 429, 431, 433, 435, 437,

439, 441, 443, 445, 447, 449, 451 , 453, 455, 457, 459, 461, 463, 465, 467,

469, 471, 473, 475, 477, 479, 481 , 483, 485, 487, 489, 491, 493, 495, 497,

499, 501, 503, 505, 507, 509, 511 , 513, 515, 517, 519, 521, 523, 525, 527,

529, 531, 533, 535, 537, 539, 541 , 543, 545, 547, 549, 551, 553, 555, 557,

559, 561, 563, 565, 567, 569, 571 , 573, 575, 577, 579, 581, 583, 585, 587, 589, 591 593, 595, 597 599, 601 603, 605, 607 609, 611, 613, 615, 617 619, 621 623, 625, 627 629, 631 633, 635, 637 639, 641, 643, 645, 647 649, 651 653, 655, 657 659, 661 663, 665, 667 669, 671, 673, 675, 677 679, 681 683, 685, 687 689, 691 693, 695, 697 699, 701 , 703, 705, 707 709, 711 713, 715, 717 719, 721 723, 725, 727 729, 731 , 733, 735, 737 739, 741 743, 745, 747 749, 751 753, 755, 757 759, 761, 763, 765, 767 769, 771 773, 775, 777 779, 781 783, 785, 787 789, 791 , 793, 795, 797 799, 801 803, 805, 807 809, 811 813, 815, 817 819, 821, 823, 825, 827 829, 831 833, 835, 837 839, 841 843, 845, 847 849, 851, 853, 855, 857 859, 861 863, 865, 867 869, 871 873, 875, 877 879, 881, 883, 885, 887 889, 891 893, 895, 897 899, 901 903, 905, 907 909, 911, 913, 915, 917 919, 921 923, 925, 927 929, 931 933, 935, 937 939, 941 , 943, 945, 947 949, 951 953, 955, 957 959, 961 963, 965, 967 969, 971 , 973, 975, 977 979, 981 983, 985, 987 989, 991 993, 995, 997 999, 1001, 1003, 1005,

1007, 1009, 1011 1013 1015, 1017 , 1019, 1021 1023, 1025, 1027, 1029 1031, 1033, 1035 1037 1039, 1041 , 1043, 1045 1047, 1049, 1051, 1053 1055, 1057, 1059 1061 1063, 1065 , 1067, 1069 1071, 1073, 1075, 1077 1079, 1081, 1083 1085 1087, 1089 , 1091, 1093 1095, 1097, 1099, 1101 1103, 1105, 1107 1109 1111, 1113 , 1115, 1117 1119, 1121, 1123, 1125 1127, 1129, 1131 1133 1135, 1137 , 1139, 1141 1143, 1145, 1147, 1149 1151, 1153, 1155 1157 1159, 1161 , 1163, 1165 1167, 1169, 1171, 1173 1175, 1177, 1179 1181 1183, 1185 , 1187, 1189 1191, 1193, 1195, 1197 1199, 1201, 1203 1205 1207, 1209 , 1211, 1213 1215, 1217, 1219, 1221 1223, 1225, 1227 1229 1231, 1233 , 1235, 1237 1239, 1241, 1243, 1245 1247, 1249, 1251 1253 1255, 1257 , 1259, 1261 1263, 1265, 1267, 1269 1271, 1273, 1275 1277 1279, 1281 , 1283, 1285 1287, 1289, 1291, 1293 1295, 1297, 1299 1301 1303, 1305 , 1307, 1309 1311, 1313, 1315, 1317 1319, 1321, 1323 1325 1327, 1329 , 1331, 1333 1335, 1337, 1339, 1341 1343, 1345, 1347 1349 1351, 1353 , 1355, 1357 1359, 1361, 1363, 1365 1367, 1369, 1371 1373 1375, 1377 , 1379, 1381 1383, 1385, 1387, 1389 1391, 1393, 1395 1397 1399, 1401 , 1403, 1405 1407, 1409, 1411, 1413 1415, 1417, 1419 1421 1423, 1425 , 1427, 1429 1431, 1433, 1435, 1437 1439, 1441, 1443 1445 1447, 1449 , 1451, 1453 1455, 1457, 1459, 1461 1463, 1465, 1467 1469 1471, 1473 , 1475, 1477 1479, 1481, 1483, 1485 1487, 1489, 1491 1493 1495, 1497 , 1499, 1501 1503, 1505, 1507, 1509 1511, 1513, 1515 1517 1519, 1521 , 1523, 1525 1527, 1529, 1531, 1533 1535, 1537, 1539 1541 1543, 1545 , 1547, 1549 1551, 1553, 1555, 1557 1559, 1561, 1563, 1565, 1567, 1569, 1571, 1573, 1575, 1577, 1579, 1581, 1583, 1585, 1587, 1589, 1591, 1593, 1595, 1597, 1599, 1601, 1603, 1605, 1607, 1609, 1611, 1613, 1615, 1617, 1619, 1621, 1623, 1625, 1627, 1629, 1631, 1633, 1635, 1637, 1639, 1641, 1643, 1645, 1647, 1649, 1651, 1653, 1655, 1657, 1659, 1661, 1663, 1665, 1667, 1669, 1671, 1673, 1675, 1677, 1679, 1681, 1683, 1685, 1687, 1689, 1691, 1693, 1695, 1697, 1699, 1701, 1703, 1705, 1707, 1709, 1711, 1713, 1715, 1717, 1719, 1721, 1723, 1725, 1727, 1729, 1731, 1733, 1735, 1737, 1739, 1741, 1743, 1745, 1747, 1749, 1751, 1753, 1755, 1757, 1759, 1761, 1763, 1765 and 1767.

In another embodiment, X _A is C and XB is K, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 , 5, 9, 13, 17, 21 , 25, 29, 33, 37, 41 , 45, 49, 53, 57, 61, 65, 69, 73, 77, 81, 85, 89, 93, 97, 101, 105, 109, 113, 117, 121, 125, 129,

133, 137, 141 145, 149, 153, 157, 161, 165, 169, 173, 177, 181, 185, 189, 193, 197, 201, 205, 209 213, 217, 221, 225, 229, 233, 237, 241, 245, 249 253, 257, 261, 265, 269 273, 277, 281, 285, 289, 293, 297, 301, 305, 309 313, 317, 321, 325, 329 333, 337, 341, 345, 349, 353, 357, 361, 365, 369 373, 377, 381, 385, 389 393, 397, 401, 405, 409, 413, 417, 421, 425, 429 433, 437, 441,445, 449 453, 457, 461, 465, 469, 473, 477, 481, 485, 489 493, 497, 501, 505, 509 513, 517, 521, 525, 529, 533, 537, 541, 545, 549 553, 557, 561, 565, 569 573, 577, 581, 585, 589, 593, 597, 601, 605, 609 613, 617, 621, 625, 629 633, 637, 641, 645, 649, 653, 657, 661, 665, 669 673, 677, 681, 685, 689 693, 697, 701, 705, 709, 713, 717, 721, 725, 729 733, 737, 741, 745, 749 753, 757, 761, 765, 769, 773, 777, 781 785, 789 793, 797, 801, 805, 809 813, 817, 821, 825, 829, 833, 837, 841, 845, 849 853, 857, 861, 865, 869 873, 877, 881, 885, 889, 893, 897, 901, 905, 909 913, 917, 921, 925, 929 933, 937, 941, 945, 949, 953, 957, 961, 965, 969 973, 977, 981, 985, 989 993, 997, 1001, 1005, 1009, 1013, 1017, 1021, 1025, 1029, 1033, 1037 1041, 1045, 1049, 1053, 1057, 1061, 1065, 1069, 1073, 1077, 1081, 1085 1089, 1093, 1097, 1101, 1105, 1109, 1113, 1117, 1121, 1125, 1129, 1133 1137, 1141, 1145, 1149, 1153, 1157, 1161, 1165, 1169, 1173, 1177, 1181 1185, 1189, 1193, 1197, 1201, 1205, 1209, 1213, 1217, 1221, 1225, 1229 1233, 1237, 1241, 1245, 1249, 1253, 1257, 1261, 1265, 1269, 1273, 1277 1281, 1285, 1289, 1293, 1297, 1301, 1305, 1309, 1313, 1317, 1321, 1325 1329, 1333, 1337, 1341, 1345, 1349, 1353, 1357, 1361, 1365, 1369, 1373 1377, 1381, 1385, 1389, 1393, 1397, 1401, 1405, 1409, 1413, 1417, 1421 1425, 1429, 1433, 1437, 1441, 1445, 1449, 1453, 1457, 1461, 1465, 1469, 1473, 1477, 1481, 1485, 1489, 1493, 1497, 1501, 1505, 1509, 1513, 1517, 1521, 1525, 1529, 1533, 1537, 1541, 1545, 1549, 1553, 1557, 1561, 1565, 1569, 1573, 1577, 1581, 1585, 1589, 1593, 1597, 1601, 1605, 1609, 1613, 1617, 1621, 1625, 1629, 1633, 1637, 1641, 1645, 1649, 1653, 1657, 1661 , 1665, 1669, 1673, 1677, 1681 , 1685, 1689, 1693, 1697, 1701, 1705, 1709, 1713, 1717, 1721, 1725, 1729, 1733, 1737, 1741, 1745, 1749, 1753, 1757, 1761 and 1765.

In another embodiment, the albumin binding polypeptide comprises one of the sequences listed in PCT publication WO2009/016043, mutated as described herein through substitution in the XA and XB positions. Thus, in this embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5-1004.

In another embodiment, X _A is C and XB is C or K in these sequences from WO2009/016043, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, 7, 9, 11 , 13, 15, 17, 19, 21 , 23, 25, 27, 29, 31 , 33, 35, 37, 39, 41 , 43, 45, 47, 49, 51 , 53, 55, 57, 59, 61 , 63, 65, 67, 69, 71 , 73, 75, 77, 79, 81 , 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121,

123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151

153, 155, 157, 159, 161 163, 165, 167, 169, 171 173, 175, 177, 179, 181

183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, 205, 207, 209, 211

213, 215, 217, 219, 221, 223, 225, 227, 229, 231, 233, 235, 237, 239, 241

243, 245, 247, 249, 251, 253, 255, 257, 259, 261 263, 265, 267, 269, 271

273, 275, 277, 279, 281, 283, 285, 287, 289, 291, 293, 295, 297, 299, 301

303, 305, 307, 309, 311, 313, 315, 317, 319, 321, 323, 325, 327, 329, 331

333, 335, 337, 339, 341, 343, 345, 347, 349, 351, 353, 355, 357, 359, 361

363, 365, 367, 369, 371, 373, 375, 377, 379, 381, 383, 385, 387, 389, 391

393, 395, 397, 399, 401, 403, 405, 407, 409, 411, 413, 415, 417, 419, 421

423, 425, 427, 429, 431, 433, 435, 437, 439, 441, 443, 445, 447, 449, 451

453, 455, 457, 459, 461 463, 465, 467, 469, 471 473, 475, 477, 479, 481

483, 485, 487, 489, 491, 493, 495, 497, 499, 501, 503, 505, 507, 509, 511

513, 515, 517, 519, 521, 523, 525, 527, 529, 531, 533, 535, 537, 539, 541

543, 545, 547, 549, 551, 553, 555, 557, 559, 561, 563, 565, 567, 569, 571

573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601

603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 623, 625, 627, 629, 631

633, 635, 637, 639, 641, 643, 645, 647, 649, 651, 653, 655, 657, 659, 661 663, 665, 667, 669, 671 673, 675, 677, 679, 681 683, 685, 687, 689, 691

693, 695, 697, 699, 701 , 703, 705, 707, 709, 71 1 713, 715, 717, 719, 721

723, 725, 727, 729, 731 , 733, 735, 737, 739, 741 743, 745, 747, 749, 751

753, 755, 757, 759, 761 , 763, 765, 767, 769, 771 773, 775, 777, 779, 781

783, 785, 787, 789, 791 , 793, 795, 797, 799, 801 803, 805, 807, 809, 81 1

813, 815, 817, 819, 821 , 823, 825, 827, 829, 831 833, 835, 837, 839, 841

843, 845, 847, 849, 851 853, 855, 857, 859, 861 863, 865, 867, 869, 871

873, 875, 877, 879, 881 , 883, 885, 887, 889, 891 893, 895, 897, 899, 901

903, 905, 907, 909, 91 1 , 913, 915, 917, 919, 921 923, 925, 927, 929, 931

933, 935, 937, 939, 941 , 943, 945, 947, 949, 951 953, 955, 957, 959, 961

963, 965, 967, 969, 971 , 973, 975, 977, 979, 981 983, 985, 987, 989, 991

993, 995, 997, 999, 1001 and 1003.

In another embodiment, XA is C and XB is K in these sequences from

WO2009/016043, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, 9, 13, 17,

21 , 25, 29, 33, 37, 41 , 45, 49, 53, 57, 61 , 65, 69, 73, 77, 81 , 85, 89, 93, 97

101 , 105, 109, 1 13, 1 17, 121 , 125, 129, 133, 137, 141 , 145, 149, 153, 157

161 , 165, 169, 173, 177, 181 , 185, 189, 193, 197, 201 , 205, 209, 213, 217

221 , 225, 229, 233, 237, 241 , 245, 249, 253, 257, 261 , 265, 269, 273, 277

281 , 285, 289, 293, 297, 301 , 305, 309, 313, 317, 321 , 325, 329, 333, 337

341 , 345, 349, 353, 357, 361 , 365, 369, 373, 377, 381 , 385, 389, 393, 397

401 , 405, 409, 413, 417, 421 , 425, 429, 433, 437, 441 , 445, 449, 453, 457

461 , 465, 469, 473, 477, 481 , 485, 489, 493, 497, 501 , 505, 509, 513, 517

521 , 525, 529, 533, 537, 541 , 545, 549, 553, 557, 561 , 565, 569, 573, 577

581 , 585, 589, 593, 597, 601 , 605, 609, 613, 617, 621 , 625, 629, 633, 637

641 , 645, 649, 653, 657, 661 , 665, 669, 673, 677, 681 , 685, 689, 693, 697

701 , 705, 709, 713, 717, 721 , 725, 729, 733, 737, 741 , 745, 749, 753, 757

761 , 765, 769, 773, 777, 781 , 785, 789, 793, 797, 801 , 805, 809, 813, 817

821 , 825, 829, 833, 837, 841 , 845, 849, 853, 857, 861 , 865, 869, 873, 877

881 , 885, 889, 893, 897, 901 , 905, 909, 913, 917, 921 , 925, 929, 933, 937

941 , 945, 949, 953, 957, 961 , 965, 969, 973, 977, 981 , 985, 989, 993, 997 and 1001 .

In another embodiment, the albumin binding polypeptide comprises a mutated version of any one of the albumin binding motif sequences disclosed in claim 24 of WO2009/016043. Thus, in this embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9-12, 13-16, 37-40, 61 -64, 101 -104, 109-1 12, 185-188, 197-200, 213-216, 217-220, 221 -224, 617-620, 925-928, 929-932, 933-936, 937-940, 941 -944, 945-948 and 949-952.

In another embodiment, X _A is C and XB is C or K in these sequences from claim 24 of WO2009/016043, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9, 1 1 , 13, 15, 37, 39, 61 , 63, 101 , 103, 109, 1 1 1 , 185, 187, 197, 199, 213, 215, 217, 219, 221 , 223, 617, 619, 925, 927, 929, 931 , 933, 935, 937, 939, 941 , 943, 945, 947, 949 and 951 .

In another embodiment, X _A is C and XB is K in these sequences from claim 24 of WO2009/016043, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, 13, 37, 61 , 101 , 109, 185, 197, 213, 217, 221 , 617, 925, 929, 933, 937, 941 , 945 and 949.

In another embodiment the albumin binding polypeptide comprises a mutated version of any one of the albumin binding motif sequences disclosed in claim 25 of WO2009/016043. Thus, in this embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9-12, 213-216 and 925-928.

In another embodiment, X _A is C and XB is C or K in these sequences from claim 25 of WO2009/016043, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, 1 1 , 213, 215, 925 and 927.

In another embodiment, X _A is C and XB is K in these sequences from claim 25 of WO2009/016043, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:9, 213 and 925, such as SEQ ID NO:925. In another embodiment, the albumin binding polypeptide comprises one of the sequences listed in PCT publication WO2012/004384, mutated as described herein through substitution in the X _A and XB positions. Thus, in this embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 -4 and 1005- 1736. In another embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from SEQ ID NO:1 -4. In another embodiment, X _A is C and XB is C or K in these sequences from WO2012/004384, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 , 3,

1005, 1007, 1009, 1011, 1013, 1015, 1017, 1019, 1021, 1023, 1025, 1027

1029, 1031, 1033, 1035, 1037, 1039, 1041, 1043, 1045, 1047, 1049, 1051

1053, 1055, 1057, 1059, 1061, 1063, 1065, 1067, 1069, 1071, 1073, 1075

1077, 1079, 1081, 1083, 1085, 1087, 1089, 1091, 1093, 1095, 1097, 1099

1101, 1103, 1105, 1107, 1109, 1111, 1113, 1115, 1117, 1119, 1121, 1123

1125, 1127, 1129, 1131, 1133, 1135, 1137, 1139, 1141, 1143, 1145, 1147

1149, 1151, 1153, 1155, 1157, 1159, 1161, 1163, 1165, 1167, 1169, 1171

1173, 1175, 1177, 1179, 1181, 1183, 1185, 1187, 1189, 1191, 1193, 1195

1197, 1199, 1201, 1203, 1205, 1207, 1209, 1211, 1213, 1215, 1217, 1219

1221, 1223, 1225, 1227, 1229, 1231, 1233, 1235, 1237, 1239, 1241, 1243

1245, 1247, 1249, 1251, 1253, 1255, 1257, 1259, 1261, 1263, 1265, 1267

1269, 1271, 1273, 1275, 1277, 1279, 1281, 1283, 1285, 1287, 1289, 1291

1293, 1295, 1297, 1299, 1301, 1303, 1305, 1307, 1309, 1311, 1313, 1315

1317, 1319, 1321, 1323, 1325, 1327, 1329, 1331, 1333, 1335, 1337, 1339

1341, 1343, 1345, 1347, 1349, 1351, 1353, 1355, 1357, 1359, 1361, 1363

1365, 1367, 1369, 1371, 1373, 1375, 1377, 1379, 1381, 1383, 1385, 1387

1389, 1391, 1393, 1395, 1397, 1399, 1401, 1403, 1405, 1407, 1409, 1411

1413, 1415, 1417, 1419, 1421, 1423, 1425, 1427, 1429, 1431, 1433, 1435

1437, 1439, 1441, 1443, 1445, 1447, 1449, 1451, 1453, 1455, 1457, 1459

1461, 1463, 1465, 1467, 1469, 1471, 1473, 1475, 1477, 1479, 1481, 1483

1485, 1487, 1489, 1491, 1493, 1495, 1497, 1499, 1501, 1503, 1505, 1507

1509, 1511, 1513, 1515, 1517, 1519, 1521, 1523, 1525, 1527, 1529, 1531

1533, 1535, 1537, 1539, 1541, 1543, 1545, 1547, 1549, 1551, 1553, 1555

1557, 1559, 1561, 1563, 1565, 1567, 1569, 1571, 1573, 1575, 1577, 1579

1581, 1583, 1585, 1587, 1589, 1591, 1593, 1595, 1597, 1599, 1601, 1603

1605, 1607, 1609, 1611, 1613, 1615, 1617, 1619, 1621, 1623, 1625, 1627

1629, 1631, 1633, 1635, 1637, 1639, 1641, 1643, 1645, 1647, 1649, 1651

1653, 1655, 1657, 1659, 1661, 1663, 1665, 1667, 1669, 1671, 1673, 1675

1677, 1679, 1681, 1683, 1685, 1687, 1689, 1691, 1693, 1695, 1697, 1699

1701, 1703, 1705, 1707, 1709, 1711, 1713, 1715, 1717, 1719, 1721, 1723

1725, 1727, 1729, 1731, 1733 and 1735.

In another embodiment, X _A is C and XB is K in these sequences from

WO2012/004384, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, 1005, 1009, 1013, 1017, 1021, 1025, 1029 1033, 1037, 1041, 1045, 1049, 1053,

1057, 1061, 1065, 1069, 1073, 1077 1081, 1085, 1089, 1093, 1097, 1101,

1105, 1109, 1113, 1117, 1121, 1125 1129, 1133, 1137, 1141, 1145, 1149,

1153, 1157, 1161, 1165, 1169, 1173 1177, 1181, 1185, 1189, 1193, 1197,

1201, 1205, 1209, 1213, 1217, 1221 1225, 1229, 1233, 1237, 1241, 1245,

1249, 1253, 1257, 1261, 1265, 1269 1273, 1277, 1281, 1285, 1289, 1293,

1297, 1301, 1305, 1309, 1313, 1317 1321, 1325, 1329, 1333, 1337, 1341,

1345, 1349, 1353, 1357, 1361, 1365 1369, 1373, 1377, 1381, 1385, 1389,

1393, 1397, 1401, 1405, 1409, 1413 1417, 1421, 1425, 1429, 1433, 1437,

1441, 1445, 1449, 1453, 1457, 1461 1465, 1469, 1473, 1477, 1481, 1485,

1489, 1493, 1497, 1501, 1505, 1509 1513, 1517, 1521, 1525, 1529, 1533,

1537, 1541, 1545, 1549, 1553, 1557 1561, 1565, 1569, 1573, 1577, 1581,

1585, 1589, 1593, 1597, 1601, 1605 1609, 1613, 1617, 1621, 1625, 1629,

1633, 1637, 1641, 1645, 1649, 1653 1657, 1661, 1665, 1669, 1673, 1677,

1681, 1685, 1689, 1693, 1697, 1701 1705, 1709, 1713, 1717, 1721, 1725,

1729 and 1733.

In another embodiment, the albumin binding polypeptide comprises a mutated version of any one of the amino acid sequences specified in claim 23 of WO2012/004384. Thus, in this embodiment, the albumin binding

polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-4, 1017-1020, 1021-1024, 1029-1032, 1033-1036, 1041-1044, 1045-1048, 1053-1056, 1061-1064, 1065-1068, 1073-1076, 1077-1080, 1085-1088, 1089-1092, 1097-1100, 1101-1104, 1109-1112, 1113-1116, 1121-1124, 1125-1128, 1133-1136, 1137-1140, 1145-1148, 1149-1152, 1161-1164, 1165-1168, 1193-1196, 1197-1200, 1577-1580, 1581-1584, 1585-1588, 1589-1592, 1593-1596, 1597-1600, 1601-1604, 1689-1692, 1693-1696, 1697-1700, 1701-1704, 1705-1708, 1709-1712, 1713-1716, 1717-1720, 1721-1724, 1725-1728, 1729-1732 and 1733-1736.

In another embodiment, X _A is C and XB is C or K in these sequences from claim 23 of WO2012/004384, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, 3, 1017, 1019, 1021, 1023, 1029, 1031, 1033, 1035, 1041, 1043, 1045, 1047, 1053, 1055, 1061, 1063, 1065, 1067, 1073, 1075, 1077, 1079, 1085, 1087, 1089, 1091, 1097, 1099, 1101, 1103, 1109, 1111, 1113, 1115, 1121, 1123, 1125, 1127, 1133, 1135, 1137, 1139, 1145, 1147, 1149, 1151, 1161, 1163, 1165, 1167, 1193, 1195, 1197, 1199, 1577, 1579, 1581, 1583, 1585, 1587, 1589, 1591 , 1593, 1595, 1597, 1599, 1601 , 1603, 1689, 1691 , 1693, 1695, 1697, 1699, 1701 , 1703, 1705, 1707, 1709, 171 1 , 1713, 1715, 1717, 1719, 1721 , 1723, 1725, 1727, 1729, 1731 , 1733 and 1735.

In another embodiment, X _A is C and XB is K in these sequences from claim 23 of WO2012/004384, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1 , 1017, 1021 , 1029, 1033, 1041 , 1045, 1053, 1061 , 1065, 1073, 1077, 1085, 1089, 1097, 1 101 , 1 109, 1 1 13, 1 121 , 1 125, 1 133, 1 137, 1 145, 1 149, 1 161 , 1 165, 1 193, 1 197, 1577, 1581 , 1585, 1589, 1593, 1597, 1601 , 1689, 1693, 1697, 1701 , 1705, 1709, 1713, 1717, 1721 , 1725, 1729 and 1733.

In another embodiment, the albumin binding polypeptide comprises an ABM sequence listed in PCT publication WO2014/048977, mutated as described herein through substitution in the XA and XB positions. Thus, in this embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1737-1768.

In another embodiment, X _A is C and XB is C or K in these sequences from PCT publication WO2014/048977, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1737, 1739, 1741 , 1743, 1745, 1747, 1749, 1751 , 1753, 1755, 1757, 1759, 1761 , 1763, 1765 and 1767.

In another embodiment, X _A is C and XB is K in these sequences from PCT publication WO2014/048977, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1737, 1741 , 1745, 1749, 1753, 1757, 1761 and 1765.

In another embodiment, the albumin binding polypeptide comprises an ABM sequence which is a mutated version of the albumin binding motif sequence disclosed in claim 2 of PCT publication WO2014/048977. Thus, in this embodiment, the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1737-1740.

In another embodiment, X _A is C and XB is C or K in this sequence from claim 2 of PCT publication WO2014/048977, so the albumin binding polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1737 and 1739. In another embodiment, X _A is C and XB is K in this sequence from claim 2 of PCT publication WO2014/048977, so the albumin binding polypeptide comprises SEQ ID NO:1737. In one embodiment, K, when present in position X _A or X _B , is

functionalized. Such functionalization may for example be by a method selected from haloacetylation, maleimide functionalization and pyridyldithiol functionalization. Thus, in one embodiment, K, when present in position X _A or XB, comprises a halooacetyl group, such as a flouroacetyl group, chloroacetyl group, bromoacetyl group or iodoacetyl group. In another embodiment, K, when present in position X _A or X _B , comprises a chloroacetyl group.

In one embodiment of the first aspect of the present disclosure, there is provided an albumin binding polypeptide as defined herein, wherein the amino acid sequence of said albumin binding polypeptide is crosslinked. In one embodiment, said crosslink extends between the amino acid residue in position X _A and the amino acid residue in position X _B of the amino acid sequence.

Crosslinking is a method that can be used in order to stabilize proteins in a specific three dimensional conformation. As used herein, the term

"crosslinking" involves covalently attaching a protein to another

macronnolecule, such as another protein, or to the same macronnolecule, such as the same protein, or to something else, such as a solid support. Hence, crosslinking may be intra-molecular and inter-molecular, such as intra- molecular crosslinking within an albumin binding polypeptide as defined herein.

Herein, the terms "crosslinker" and "crosslinking agent" refer to a molecule with at least two reactive ends, which may be used to connect polymer chains, such as amino acid chains. Crosslinkers are usually reactive toward functional groups common on amino acids, such as carboxyl groups, amine groups and sulfhydryl groups.

Known in the art are homobifunctional crosslinkers, which have the same reactive groups on each end of the crosslinker. Non-limiting examples of homobifunctional crosslinkers are dihalogenated crosslinkers, dimaleimide crosslinkers, dipyridyldithiol crosslinkers and perfluoroaromatic crosslinkers.

Also known are heterobifunctional crosslinkers, which have different reactive groups on each end of the crosslinker. Reactive groups of heterobifunctional crosslinkers may be chosen such that a specific

crosslinking target (for example a protein or an amino acid residue) will bind to one end and another specific crosslinking target will bind to the other end of said crosslinker.

Thus, the skilled person is aware of many types of crosslinkers. Known in the art are for example haloacetyl and maleimide crosslinkers, which react with sulfhydryl groups at physiological pH to form thioether linkages. Also known are pyridyl disulfide crosslinkers, which react with sulfhydryl groups to form disulfide bonds. Other types of crosslinkers include N- hydroxysuccinimide esters, imido esters, carbodiimides and diazirines.

Examples of some common crosslinkers are the imido ester crosslinker dimethyl suberimidate and the N-hydroxysuccinimide ester crosslinker BS3. These crosslinkers induce a nucleophilic attack of the amino group of the lysine side chain, resulting in covalent bond formation via the crosslinker.

Crosslinking may involve chemoselective crosslinking chemistries, such as thioether bond formation between a haloacetylated, maleimide- functionalized or pyridyld ith iol-functional ized lysine residue and the thiol group of a cysteine residue. Another example is thioether bond formation between a haloacetylated, maleimide-functionalized or pyndyldithiol-functionalized lysine residue and a lysine residue modified by coupling of a thiol-containing reagent, such as mercaptoacetic acid or mercaptopropionic acid to the lysine amino group. Chemoselective crosslinking chemistries may also involve thioether bond formation between the thiol groups of two cysteine residues and a bifunctional dihalogenated linker, dimaleimide linker, dipyridyldithiol linker or perfluoroaromatic linker. Also, chemoselective crosslinking chemistries may involve disulfide bond formation between thiol groups of cysteine residues and/or thiol groups of lysine residues modified by coupling of thiol-containing reagents thereto as described above; oxime bond formation between an aminooxy-modified amino acid residue and an aldehyde-modified or ketone-modified amino acid residue, bond formation via Staudinger reaction between an azido-modified amino acid residue and a triarylphosphine-modified amino acid residue as well as bond formation via native chemical ligation reaction between a thioester-modified amino acid residue and a cysteine-modified amino acid residue. The skilled person will appreciate that said crosslink can be obtained by any chemoselective crosslinking chemistry mentioned above or any other suitable chemistry or method. Thus, in one embodiment, there is provided a crosslinked albumin binding polypeptide, wherein said crosslink is selected from the group comprising

- thioether bond between a haloacetylated lysine residue and a thiol group of a cysteine residue or thiol-modified lysine residue,

- thioether bond between a maleimide-functionalized lysine residue and a thiol group of a cysteine residue or thiol-modified lysine residue,

- thioether bond between a pyridyld ith iol-functional ized lysine residue and a thiol group of a cysteine residue or thiol-modified lysine residue,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional dihalogenated linker,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional dimaleimide linker,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional dipyridyldithiol linker,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional perfluoroaromatic linker,

- disulfide bond between the thiol groups of cysteine residues or thiol- modified lysine residues,

- oxime bond between an aminooxy-modified amino acid residue and an aldehyde-modified amino acid residue,

- oxime bond between an aminooxy-modified amino acid residue and a ketone-modified amino acid residue,

- bond formed by Cu-catalyzed cycloaddition between an azido-modified amino acid residue and an alkyne-modified amino acid residue,

- bond formed by Staudinger reaction between an azido-modified amino acid residue and a triarylphosphine-modified amino acid residue, and

- bond formed by native chemical ligation reaction between a thioester- modified amino acid residue and a cysteine-modified amino acid residue.

In one embodiment, said crosslink is a thioether bond, such as a thioether bond between a haloacetylated lysine residue and the thiol group of a cysteine residue. For example, such a thioether bond may be between a chloroacetylated lysine residue and the thiol group of a cysteine residue. In another embodiment, said thioether bond is between a chloroacetylated lysine residue and the thiol group of a mercaptoacetylated lysine residue. In another embodiment, said crosslink is a disulfide bond between the thiol groups of two cysteine residues, such as a disulfide bond obtained by using a dihalide crosslinker. In one embodiment, said crosslinker is selected from the group consisting of o-xylylene dibromide, m-xylylene dibromide, p- xylylene dibromide, 2,3-bis(bromomethyl)quinoxaline and 2,6- bis(bromomethyl)pyridine, such as from the group consisting of o-xylylene dibromide, m-xylylene dibromide and 2,6-bis(bromomethyl)pyridine.

As stated above, the skilled person is aware that the function of any polypeptide, such as the albumin binding capacity of the polypeptides according to the present disclosure, is dependent on the tertiary structure of said polypeptide. The skilled person is also aware of the three-helix bundle domain structure of G148-GA3 and its various known derivatives, and thus appreciates that the albumin binding polypeptides described herein need to retain essentially the same tertiary structure when crosslinked as their non- crosslinked counterpart or counterparts in order to retain essentially the same albumin binding properties. In one embodiment, there is provided a crosslinked albumin binding polypeptide, in which said albumin binding motif retains a two alpha helix conformation. In another embodiment, there is provided a crosslinked albumin binding polypeptide, wherein said albumin binding motif forms part of a polypeptide which retains a three-helix bundle conformation.

The present disclosure contemplates albumin binding polypeptides with a high level of resistance to proteolytic cleavage, such as proteolytic cleavage within the gastrointestinal tract. Without wishing to be bound by theory, in embodiments in which the albumin binding polypeptide is crosslinked, it is thought that it is the crosslink that provides such resistance. Albumin binding polypeptides which exhibit such increased resistance to proteolytic cleavage may more suitable for oral delivery.

Examples of proteolytic enzymes present in the gastrointestinal tract are pepsin, found in the stomach, trypsin and chymotrypsin, both found in the duodenum.

Thus, in one embodiment there is provided an albumin binding polypeptide that is resistant to proteolytic cleavage, such as proteolytic cleavage by at least one protease of the gastrointestinal tract. In one embodiment, said at least one protease is selected from the group consisting of pepsin, trypsin and chymotrypsin, and all possible combinations thereof. In another embodiment, said at least one protease is pepsin. In another embodiment, said at least one protease is trypsin. In another embodiment, said at least one protease is chymotrypsin.

In one embodiment of the present aspect of the disclosure, there is provided an albumin binding polypeptide, which exhibits a melting

temperature (Tm) of at least 37 °C, for example at least 39 °C, for example at least 41 °C, for example at least 43 °C, for example at least 45 °C, for example at least 47 °C, for example at least 49 °C, for example at least 51 °C, for example at least 53 °C, for example at least 55 °C, for example at least 57 °C, for example at least 59 °C, for example at least 61 °C, for example at least 63 °C, for example at least 65 °C, for example at least 67 °C, for example at least 69 °C, for example at least 71 °C, for example at least 73 °C, for example at least 75 °C.

The terms "albumin binding" and "binding affinity for albumin" as used in this specification refer to a property of a polypeptide which may be tested for example by the use of surface plasmon resonance technology, such as in Biacore (GE Healthcare) or ProteOn XPR 36 (Bio-Rad) instrument. For example as described in the examples below, albumin binding affinity may be tested in an experiment in which albumin, or a fragment thereof, is

immobilized on a sensor chip of the instrument, and the sample containing the polypeptide to be tested is passed over the chip. Alternatively, the polypeptide to be tested is immobilized on a sensor chip of the instrument, and a sample containing albumin, or a fragment thereof, is passed over the chip. Albumin may, in this regard, be serum albumin from a mammal, such as human serum albumin. The skilled person may then interpret the results obtained by such experiments to establish at least a qualitative measure of the binding affinity of the polypeptide for albumin. If a quantitative measure is desired, for example to determine a K _D value for the interaction, surface plasmon resonance methods may also be used. Binding values may for example be defined in a Biacore2000 instrument (GE Healthcare). Albumin is suitably immobilized on a sensor chip of the measurement, and samples of the polypeptide whose affinity is to be determined are prepared by serial dilution and injected in random order. K _D values may then be calculated from the results using for example the 1 :1 Langmuir binding model of the BIAevaluation 4.1 software, or other suitable software, provided by the instrument manufacturer.

In embodiments of this aspect of the disclosure, there is provided an albumin binding polypeptide which binds to albumin such that the K _D value of the interaction is at most 1 x 10 ^"8 M, such as at most 1 x 10 ^"9 M, such as at most 1 x 10 ^"10 M, such as at most 1 x 10 ^"11 M, such as at most 1 x 10 ^"12 M.

In one embodiment, said albumin is human serum albumin.

In a second aspect of the present disclosure, there is provided a compound comprising

- at least one moiety (I) which is an albumin binding polypeptide as described in the first aspect;

- one moiety (II) which confers a desired therapeutic activity; and

- optionally, at least one further moiety (III) which confers a desired therapeutic activity, which activity may be the same or different from said activity of moiety (II).

Thus, the second aspect of the present disclosure provides a compound which comprises as moiety (I) an albumin binding polypeptide as defined in connection with the first aspect. When present as moiety (I) in such a compound, this albumin binding may, in any combination, exhibit any one or more of the properties, features, characteristics and/or embodiments described above in connection with the first aspect of the disclosure. For the sake of brevity, this information will not be repeated in connection with this second aspect, but is incorporated by reference to the above disclosure.

The compound as defined above comprises at least moieties (I) and (II) and optionally moiety (III). The moieties may for example be connected by covalent coupling using known organic chemistry methods, or, if one or both moieties are polypeptides, be expressed as one or more fusion polypeptides in a system for recombinant expression of polypeptides, or joined in any other fashion, directly or via a linker, for example a linker comprising a number of amino acid residues. For discussions concerning the coupling of albumin binding moieties to other moieties, for example in order to provide a compound as defined above, see for example PCT publications

WO2009/016043, WO2012/004384 and WO2014/048977, from which the relevant sections are incorporated herein by reference. As defined herein, said compound comprises at least one moiety (I), such as two, three, four or more moieties (I). Similarly to the above, moieties (I) may be coupled to each other by means of chemical conjugation (using known organic chemistry methods) or by any other means, such as expression of said moieties as a fusion protein or joined in any other fashion, either directly or via a linker, for example an amino acid linker. Said moieties (I) may be the same or different.

The designations moiety (I), moiety (II) and moiety (III) are made for clarity reasons to distinguish between the herein disclosed albumin binding polypeptide (moiety (I)) and moieties exhibiting other functions. These designations are not intended to refer to the actual order of the different domains in the polypeptide chain of the fusion protein or conjugate. Thus, for example, said first moiety may without restriction appear at the N-terminal end, in the middle, or at the C-terminal end of the fusion protein or conjugate. As a non-limiting illustration, moieties (I), (II) and (III) may for example be arranged as (l)-(l l)-(l)-(ll l), (l)-(l l)-(l), (l)-(l)-(ll), (l l)-(l l l)-(l)-(l ll), or in any other suitable manner. Thus, said compound may comprise any combination of moieties (I), (II) and optionally (III). In one embodiment of this aspect, the part of the compound designated moiety (II) and/or (III) comprises a component selected from the group consisting of human endogenous enzymes, hormones, growth factors, chemokines, cytokines, blood clotting and complement factors, innate immune defense and regulatory peptides, for example selected from the group consisting of insulin, insulin analogs, IL-2, IL-5, GLP-1 , BNP, IL 1 -RA, KGF, Stemgen®, GH, G-CSF, CTLA-4, myostatin, Factor VII, Factor VIII and Factor IX, and derivatives of anyone thereof.

In another embodiment, moiety (II) and/or (III) comprises a non-human biologically active protein, selected from the group consisting of modulins, bacterial toxins, hormones, innate immune defense peptides, regulatory peptides, enzymes and activating proteins.

In yet another embodiment, moiety (II) and/or (III) comprises a binding polypeptide capable of selective interaction with a target molecule. Such a binding polypeptide may for example be selected from the group consisting of antibodies and fragments and domains thereof substantially retaining antibody binding activity; microbodies, maxybodies, avimers and other small disulfide-bonded proteins; and binding proteins derived from a scaffold selected from the group consisting of staphylococcal protein A and domains thereof, other three helix domains, lipocalins, ankyrin repeat domains, cellulose binding domains, γ crystallines, green fluorescent protein, human cytotoxic T lymphocyte-associated antigen 4, protease inhibitors such as Kunitz domains, PDZ domains, SH3 domains, peptide aptamers,

staphylococcal nuclease, tendamistats, fibronectin type III domain, transferrin, zinc fingers and conotoxins.

In some examples of such an embodiment, the binding polypeptide comprises a variant of protein Z, in turn derived from domain B of

staphylococcal protein A and described in Nilsson B et al, Protein Engineering 1 :107-133, 1987. Such variants, having affinity for a number of different targets, have been selected from libraries and engineered further as

described in numerous prior publications, starting with WO95/19374 and the article by Nord ef a/ in Nat Biotech (1997) 15:772-777. In this embodiment of a compound for use according to the present disclosure, the variant of protein Z which corresponds to moiety (II) and/or (III) comprises a scaffold amino acid sequence selected from SEQ ID NO:1775-1781 (see Table 1 ), wherein X denotes any amino acid residue. As described in the references above, the amino acid positions denoted X are all involved in the binding function of the protein Z variant, and will vary depending on what target the Z variant is designed to bind. Preferably, in these embodiments, the scaffold amino acid sequence of moiety (II) or (III) comprises SEQ ID NO:1775.

SEQ ID NO Amino acid sequence

1775 EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLNDSQ

1776 VDNKFNKEXX XAXXEIXXLP NLNXXQXXAF IXSLXDDPSQ SANLLAEAKK LNDAQAPK

1777 EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLSESQ

1778 EXXXAXXEIX XLPNLTXXQX XAFIXKLXDD PSQSSELLSE AKKLESSQ

1779 EXXXAXXEIX XLPNLTXXQX XAFIXKLXRQ PEQSSELLSE AKKLNDSQ

1780 EXXXAXXEIX XLPNLTXXQX XAFIXKLXRQ PEQSSELLSE AKKLSESQ

1781 EXXXAXXEIX XLPNLTXXQX XAFIXKLXRQ PEQSSELLSE AKKLESSQ

Table 1 . Scaffold amino acid sequences of protein Z variants

In embodiments of this aspect, wherein moiety (II) and/or (III) comprises a binding polypeptide capable of selective interaction with a target molecule, said target molecule may be selected from the group consisting of tumor- related or other cell surface related antigens, such as CD14, CD19, CD20, CD22, CD30, CD33, CD37, CD40, CD52, CD56, CD70, CD138, cMet, HER1 , HER2, HER3, HER4, CAIX, CEA, IL-2 receptor, IGF1 R, VEGFR2, EGFR, FcRn, MUC1 , PDGFR-beta, PSMA, TAG-72, FOLR1 , mesothelin, CA6, GPNMB, integrins and ephA2; cytokines such as TNF-a, IL-1 a, IL-1 β, IL-1 Ra, IL-5, IL-6, IL-13, IL-17A, IL-18, IL-23, IL-36, G-CSF, GM-CSF, and their receptors; chemokines such as IL-8, CCL-2 and CCL1 1 , and their receptors; complement factors such as C3, C5 and factor D; growth factors such as HGF and myostatin; hormones such as GH, insulin and somatostatin;

peptides such as Αβ peptide of Alzheimer's disease; other disease- associated amyloid peptides; hypersensitivity mediators such as histamine and IgE, immunoglobulins such as IgG; blood clotting factors, such as von Willebrand factor; and toxins, such as bacterial toxins and snake venoms. In an alternative embodiment, moiety (II) and/or (III) comprises a non- proteinaceous component having a therapeutic activity. Examples of particular interest are cytotoxic agents and anti-inflammatory agents, since albumin has been shown to accumulate in tumor tissues and at sites of inflammation (Kratz and Beyer, Drug Delivery 5: 281 -99, 1998; Wunder et al, J. Immunol. 170: 4793-801 , 2003). This, in turn, provides a rationale for oral delivery of such compounds together with the albumin binding moiety for targeting and accumulation at relevant tumor tissues or inflammation sites. Non-limiting examples of cytotoxic agents are calicheamycin, auristatin, doxorubicin, maytansinoid, taxane, ecteinascidin, geldanamycin,

methotrexate, camptothecin, cyclophosphamide, cyclosporine and their derivatives, and combinations thereof. Non-limiting examples of antiinflammatory agents are non-steroidal anti-inflammatory drugs (NSAIDs), cytokine suppressive anti-inflammatory drugs (CSAIDs), corticosteroids, methotrexate, prednisone, cyclosporine, morroniside cinnamic acid, leflunomide and their derivatives, and combinations thereof.

In such embodiments, the non-proteinaceous moiety (II) and/or (III) and albumin binding moiety (I) may be non-covalently associated or covalently coupled together. Conjugation of a non-proteinaceous moiety (II) or (III) to an albumin binding moiety (I) may increase the solubility, and thereby the bioavailability, of poorly soluble compounds otherwise not suitable for oral administration. In a third aspect of the present disclosure, there is provided a

pharmaceutical composition comprising the compound as described herein and at least one pharmaceutically acceptable excipient.

Thus, the third aspect of the present disclosure provides a

pharmaceutical composition which comprises as one component a compound as defined in connection with the second aspect. When present in a pharmaceutical composition, this compound may, in any combination, exhibit any one or more of the properties, features, characteristics and/or

embodiments described above in connection with the second aspect of the disclosure. For the sake of brevity, this information will not be repeated in connection with this third aspect, but is incorporated by reference to the above disclosure.

The pharmaceutical composition also comprises at least one

pharmaceutically acceptable excipient. "Excipients" are inert substances used as diluents or vehicles in a drug formulation. An excipient is mixed with the therapeutically active compound or compounds to facilitate administration or manufacture, improve product delivery, promote the consistent release and bioavailability of the drug, enhance stability, assist in product identification, or enhance other product characteristics. Excipients may be classified into binders, diluents/fillers, lubricants, glidants, disintegrants, polishing agents, colorings, suspending agents, film formers and coatings, plasticizers, dispersing agents, preservatives, flavorings, sweeteners etc.

In some embodiments of the inventive pharmaceutical composition, it further comprises at least one component for increasing oral bioavailability of the compound which confers a desired therapeutic activity. In those embodiments, the component in question may be selected from the group consisting of protease inhibitors, absorbance enhancers, mucoadhesive polymers, formulation vehicles and any combination thereof. Uses of such components and the scientific rationale behind them are described in the following sections, concerning general strategies to improve the oral bioavailability of therapeutics.

The resistance of the pharmaceutical composition to the acid and enzymatic environment of the gastrointestinal tract may be (further) increased by adding one or more inhibitors (cocktails or individually targeting) of the relevant peptide- and protein-targeting enzymes active in the stomach (e.g. pepsin) and the intestine (e.g. trypsin, chymotrypsin and carboxypeptidase). Such inhibitors may be selected from trypsin and a-chymotrypsin inhibitors such as pancreatin inhibitor, soybean trypsin inhibitor, FK-448, camostat mesylate, aprotinin, chicken and duck ovomucoids, carboxymethylcellulose and Bowman-Birk inhibitor; or mucoadhesive polymer protease-inhibitor conjugates (Park et al, Reactive and Functional Polymers, 71 :280-287, 201 1 ).

To increase the absorption of polypeptides though the intestinal wall and hence improve the therapeutic efficacy, absorbance enhancers rendering the epithelial barrier more permeable may be included in the pharmaceutical composition. The absorbance enhancers may for instance disrupt the lipid bilayer of the cell membrane improving the transcellular transport, or act as chelating agents rupturing tight junctions facilitating paracellular transport. Non-limiting examples of absorbance enhancers for use in this aspect of the disclosure are detergents, surfactants, bile salts, calcium chelating agents, fatty acids, medium chain glycerides, salicylates, alkanoyl cholines, N- acetylated a-amino acids, N-acetylated non-a-amino acids, chitosans, phospholipids, sodium caprate, acyl carnitine and Zonula Occludens toxin (Park et al, 201 1 , supra; Salama et al, Adv Drug Deliv Rev. 58:15-28, 2006).

As an additional or alternative component in the pharmaceutical composition, mucoadhesive polymers have the potential to protect from proteolytic degradation, but are primarily applied to provide site-specific delivery to the mucus membrane, extend the residence time at the site of drug absorption and to improve membrane permeation, all promoting increased absorbance through the intestinal wall. Non-limiting examples for use in the inventive pharmaceutical composition are poly(methacrylic acid-g- ethylene glycol)[P(MAA-g-EG)] hydrogel microparticles, lecithin conjugated alginate microparticles, thiolated polymers (thiomers), gastrointestinal mucoadhesive patch systems (GI-MAPS) and mucoadhesive polymer protease-inhibitor conjugates (Park et al, 201 1 , supra).

Formulation vehicles, such as emulsions, liposomes, microspheres, nanospheres, nanocapsules or complete encapsulation, may contribute to the protection from proteolytic degradation and provide a controlled release rate, as well as promoting enhanced delivery across the intestinal wall. Such formulation vehicles constitute yet an alternative or complementary

component for use in the inventive pharmaceutical composition. In particular, nanoparticles having modified surface properties or being coupled to a targeting molecule may be used. Surface modification of nanoparticles can for example be achieved either by coating with hydrophilic stabilizing,

bioadhesive polymers or surfactants, or by incorporating hydrophilic copolymers in the nanoparticle formulation. Examples of such hydrophilic polymers include PEG and chitosan (des Rieux et al, J Control Release.

1 16:1 -27, 2006). Targeting nanoparticles are designed to specifically adhere to receptors expressed on enterocytes or M-cells of the epithelial layer of the intestinal wall by for instance coupling ligands such as lectins or RGD

(arginine-glycine-aspartate) derivatives to the nanoparticle (des Rieux et al, 2006, supra). M-cells also provide a route for delivery into the lymphatic system (Rubas and Grass, Advanced Drug Delivery Reviews, 7:15-69, 1991 ).

The pharmaceutical composition defined herein may for example be orally administered in solid form, such as in pills, tablets, capsules, powders or granules; in semi-solid form, such as in pastes; or in liquid form, such as in elixirs, solutions or suspensions. Solid forms may contain excipients such as chitosan, alginates, microcrystalline cellulose, lactose, saccharose, starch, gelatin, milk sugar, polyethylene glycols, polyvinylpyrrolidone (PVP), magnesium stearate, calcium stearate and sodium starch glycolate.

Preparations in liquid forms may contain excipients such as sweetening or flavoring agents, emulsifying or suspending agents or diluents such as water, ethanol, propylene glycol and glycerin.

The formulation may be intended for immediate-, delayed- or controlled- release applications. Tablets or capsules intended for immediate release should rapidly disintegrate and release the entire active substance in the upper part of the Gl tract, i.e. the stomach. On the contrary, tablets or capsules intended for delayed or controlled release can be designed for time- dependent release (depot) or site-specific release (e.g. intestine). Time- dependent release may for instance be based on dissolution or diffusion controlled release dependent on the matrix or membrane composition. Site- specific release may for instance be based on pH- or enzyme sensitivity. Particularly preferred for formulation of the pharmaceutical composition according to the third aspect are enteric-coated capsules, intended for release in the small intestine or colon. Such enteric-coated capsules should be stable at the highly acidic pH of the stomach, but be rapidly dissolved at the less acidic pH of the intestinal tract. Examples of pH sensitive enteric film forming agents include cellulose polymers such as hydroxypropyl methyl cellulosephthalate (HPMCP), cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropyl methyl acetatesuccinate (HPMCAS), polyvinyl acetate phthalate (PVAP), and other polymers such as Eudragit® derivatives, shellac (SH), chitosan and chitin. In a fourth aspect of the disclosure, there is provided an albumin binding polypeptide, a compound or a pharmaceutical composition as defined in the first, second and third aspects respectively, for use in treatment, for example by oral administration.

In a related fifth aspect, there is provided a method of treatment of a mammalian subject in need of such treatment, comprising administration, for example oral administration, of a therapeutically effective amount of an albumin binding polypeptide, a compound or a pharmaceutical composition as defined in the first, second and third aspects respectively.

In a related sixth aspect, there is provided use of an albumin binding polypeptide, a compound or a pharmaceutical composition as defined in the first, second and third aspects respectively, for the preparation of a

medicament for treatment, for example for treatment by oral administration.

In the fourth, fifth and sixth aspects, it will be understood that the albumin binding polypeptide, compound and pharmaceutical composition, respectively, may each individually exhibit any one or more of the properties, features, characteristics and/or embodiments described above in connection with the first, second and third aspects of the present disclosure, in any combination. For the sake of brevity, this information will not be repeated here, but is incorporated by reference to the above disclosure.

In one embodiment, said use or method of treatment is carried out according to a specified dosage regime. The optimal dosage regime will depend on the potency of the moiety conferring the therapeutic effect, on the bioavailability of the compound as defined herein and on the nature of the disease to be treated. However, the compound as defined herein, which comprises an albumin binding moiety that is thought to extend the half-life of the compound, is contemplated to not require a single high dose to reach the level of a therapeutic effect, but, due to the sustained residence time in the circulation, allows for administration of lower repeated doses leading to a build-up of the concentration of the compound, eventually reaching a sustainable desired therapeutic effect. In other words, following oral administration, a lower bioavailability than for a short-lived therapeutic would be acceptable. Such repeated dosing may be given at least twice monthly, once weekly, twice weekly, three times weekly, once daily, twice daily, such as at least three times daily. For certain diseases it may be desirable to administer a bolus dose, followed by repeated lower doses. The bolus dose may be taken as multiples of an orally formulated drug, at least once daily, twice daily, three times daily, four times daily or at least five times daily. Alternatively, the high bolus dose may be administered via another route, such as by an intravenous or subcutaneous injection. Subsequent dosing, serving the purpose of providing a sustained therapeutic effect, may be given at least twice monthly, once weekly, twice weekly, three times weekly, once daily, twice daily, three times daily, such as at least four times daily.

While the present disclosure has been illustrated with reference to various exemplary aspects and embodiments, it will be understood by those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the disclosure. In addition, many modifications may be made to adapt a particular situation or molecule to the teachings of the present disclosure without departing from the essential scope thereof. Therefore, it is intended that the disclosure not be limited to any particular embodiment contemplated, but include all embodiments falling within the scope of the appended claims.

The present disclosure will now be further illustrated by the following non-limiting Examples.

Brief description of the figures

Figure 1 is a listing of the amino acid sequences of examples of albumin binding polypeptides of the present disclosure (SEQ ID NO:1 -1768 and 1773), control polypeptides (SEQ ID NO:1769-1772 and 1774) and scaffold variants of target binding polypeptides based on protein Z (SEQ ID NO:1775- 1781 ). In the albumin binding polypeptides of the present disclosure, the deduced albumin binding motifs, extending from position 16 to position 45 in each sequence, are enclosed by hyphens. For the avoidance of any doubt, these hyphens do not indicate the presence of deletion mutations.

Figure 2 shows a schematic structural model and positions used for intramolecular crosslinking: 1 ) C17-K45, 2) K5-C28 and 3) C1 -K29.

Figure 3 is a diagram showing the result of RP-HPLC analysis of the crude synthetic polypeptide PEP18049. The chromatograms show the absorbance at 220 nm for the linear chloroacetylated PEP18049 before crosslinking (Figure 3A), and the product after 3 h incubation, where the major peak, indicated by an arrow, contains the intramolecular crosslinked PEP18049_CL (Figure 3B).

Figure 4 shows overlays of the CD spectra of test and control polypeptides before (solid line) and after (broken line) heat treatment of A) crosslinked PEP18049_CL; and B) linear reference polypeptide PEP07830, and C) shows normalized variable temperature measurements, VTM, of PEP18049_CL (solid line) and PEP07830 (broken line).

Figure 5A shows the result of binding analysis by SPR of human serum albumin binding by the crosslinked PEP18049_CL (black) in comparison with the linear reference polypeptide PEP07830 (grey).

Figure 5B shows the result of a binding analysis by SPR of human serum albumin binding by the Cys-Cys crosslinked variants

PEP14788_CL_A, PEP14788_CL_B and PEP14788_CL_E (shown in black and indicated by A, B and E, respectively) initially produced by chemical synthesis. Albumin binding by PEP18049_CL (dark grey) and the linear reference polypeptide PEP07830 (light grey) are shown for comparison.

Figure 5C shows the result of a binding analysis by SPR of human serum albumin binding by the Cys-Cys crosslinked variants PEP14789_CL_A and PEP14789_CL_B (shown in black and indicated by A and B,

respectively) initially produced by recombinant expression in E. coli.

PEP18049_CL (dark grey) and the linear reference polypeptide PEP07830 (light grey) are shown for comparison.

Figure 6 shows the result of the enzyme degradation experiment described in Example 5, using A) pepsin and B) trypsin + chymotrypsin. Normalized amount of residual intact protein of PEP18049_CL (solid line), PEP14788_CL_A (broken line) and PEP07830 (dotted line) is plotted over time.

Example 1

Production of polypeptides Seven polypeptides were produced by solid phase peptide synthesis

(SPPS): PEP18049 (SEQ ID NO:1 ), PEP18050 (SEQ ID NO:1769),

PEP18051 (SEQ ID NO:1770), PEP18052 (SEQ ID NO:1771 ), PEP18053 (SEQ ID NO:1772), PEP14788 (SEQ ID NO:3) and PEP07830 (SEQ ID NO:1774). The first five were designed to allow for intermolecular crosslinking between a functionalized lysine residue and a partner cysteine as further described in Example 2. PEP14788 was designed as a variant of PEP18049, but with two cysteines for crosslinking with a dihalide and to investigate the possibility to produce the tethered polypeptide using recombinant expression. Hence, this polypeptide, but with an N-terminal GSS, was also produced recombinantly and is here designated PEP14789 (SEQ ID NO:1773).

PEP07830 was produced to be used as a linear (non-crosslinked) control in subsequent characterization analyses.

Materials and methods

Production by chemical synthesis: The polypeptides were synthesized on a 0.1 mmol scale using microwave-assisted SPPS on an automated peptide synthesizer with an integrated microwave oven (Liberty™, CEM

Corporation, USA) using an amide resin as solid support (Rink Amide MBHA LL resin (Rink, Tetrahedron Lett 28:3787-3790, 1987), 100-200 mesh

(Novabiochem), loading 0.36 mmol ^"1 ). N-Methylpyrrolidone (NMP, Carlo Erba Reagent) was used for washing and as main solvent during the synthesis. Acylation reactions were performed using a five-fold excess of the amino acid activated with 2-(1 H-benzotriazole-1 -yl)-1 ,1 ,3,3-tetramethyluronium- hexafluorophosphate (HBTU, Iris Biotech), hydroxybenzotriazole (HOBt, Iris Biotech) and diisopropylethylannine (DIEA, Applied Biosystems), and added to the resin at a molar ratio of 1 :1 :1 :2 (amino acid:HBTU:HOBt:DIEA). All Asn, Arg, Cys, Tyr and Lys(Mtt; 4-methyltrityl) were double coupled due to their bulky protective groups. Potentially unreacted amino groups were capped using acetic anhydride (0.5 M acetic anhydride (AlfaAesar), 0.125 M DIEA and 0.015 M HOBt) before the N-terminal Fmoc group was removed by piperazine treatment (5 % piperazine (AlfaAesar) in NMP). All amino acids were introduced with standard side chain protection groups (terf-butyl (tBu) for Asp, Glu, Ser, Thr and Tyr, terf-butyloxycarbonyl (Boc) for Lys, 2,2,4,6,7- pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) for Arg, and trityl (Trt) for Asn and Cys), except where indicated.

After completed synthesis, the N-terminal leucine of PEP18049 was capped with acetic anhydride (50 mM acetic anhydride (AlfaAesar), 150 mM DIEA and 1 .5 mM HOBt). For the other synthetic variants (PEP18050, PEP18051 , PEP18052, PEP18053 and PEP14788), the N-terminal leucine or cysteine was introduced as a Boc-protected amino acid, leaving the N- terminal protected until the peptide was cleaved from the resin. The Mtt group on Lys45 (in PEP18049, PEP18052 and PEP18053), Lys5 (in PEP18050 and PEP18052) and/or Lys29 (in PEP18051 and PEP18053) was removed by treatment with TFA/TIS/DCM (1 :5:94) (TFA: trifluoroacetic acid (Merck), TIS: triisopropylsilane (Aldrich), DCM: dichloromethane (Applied Biosystems)) for 10x2 min. The free ε-amino group(s) was chloroacetylated by incubation for 1 h with chloroacetic acid (10 eq; Aldrich), preactivated with

Ν,Ν'-dicyclohexylcarbodiimide (DCC, 5 eq) (Aldrich) and DIEA (10 eq) in DCM, and supplemented with 1 v/v DMF after activation. The

chloroacetylation reaction was repeated two or three times.

Finally, the modified peptide was cleaved from the solid support and the side chains were deprotected by treatment with TFA/EDT/H ₂ O/TIS

(94:2.5:2.5:1 ) (EDT: 1 ,2-ethanedithiol (Aldrich)), for 2 h at RT with occasional mixing. After TFA treatment, solid matter was removed by filtration and the peptides were precipitated using ice cold terf-butyl methyl ether (Merck). The precipitates were then centrifuged, the supernatant was removed, and fresh cold ether was added. This was repeated three times before the peptides were dissolved in 20 % acetonitrile (Merck) in water with 0.1 % TFA and lyophilized.

The crude peptides were either analyzed by RP-HPLC and LC-ESI-MS or used directly in crosslinking reactions. RP-HPLC was performed using a 4.6 150 mm Zorbax 300SB-C18 column connected to a 1200 series HPLC and LC-ESI-MS was performed on a 6520 Accurate Mass Q-TOF LC/MS (column and instruments from Agilent Technologies).

Production by recombinant expression: PEP14789 was cloned and expressed in E. coli with an N-terminal MGSS-extension using standard methods essentially as described in Example 1 of WO2012/004384.

Purification was performed by standard chromatography methods using affinity chromatography and reversed phase chromatography, also essentially as described in WO2012/004384.

Results

PEP18049, PEP18050, PEP18051 , PEP18052, PEP18053, PEP14788 and PEP07830 were successfully produced by solid phase peptide synthesis and PEP14789 was produced by recombinant production. PEP18049, PEP18050, PEP18051 , PEP18052 and PEP18053 were further functionalized with a chloroacetyl group at selected lysine residues (one or two at positions 5, 29 or 45). Mass spectrometry analysis confirmed the correct identity of all produced polypeptides.

Example 2

Intramolecular crosslinking of albumin binding polypeptides

The polypeptides to be crosslinked were primarily designed so that a functionalized lysine residue has a partner cysteine that comes in close

contact if the protein folds in a three-helical bundle, based on the three- dimensional structure solved for the G148-GA3 domain (PDB file: 1 GJS;

Johansson et al, supra). A schematic structural model illustrating crosslinked positions investigated herein is shown in Figure 2. A polypeptide variant

crosslinked between two cysteine residues via a dihalide was also assessed.

Amino acid residues used for crosslinking are specified in Table 2.

SEQ ID NO Designation Crosslinked positions

(linear polypeptide) (crosslinked polypeptide)

1 PEP18049_CL Cys17-Lys45

1769 PEP18050_CL Lys5-Cys28

1770 PEP18051_CL Cys1 -Lys29

1771 PEP18052_CL Lys5-Cys28 and Cys17-Lys45

1772 PEP18053_CL Cys1 -Lys29 and Cys17-Lys45

3 PEP14788_CL Cys17-Cys45

1773 PEP14789 CL Cys17-Cys45

Table 2: Amino acid positions used for crosslinking Materials and methods

Crosslinking via Lvs-Cvs: For each variant, crude synthetic peptide was dissolved in phosphate-buffered saline (PBS; pH 7.4) supplemented with 10 mM ethylenediaminetetraacetic acid (EDTA; Merck) to a concentration of 2 mg ml ^"1 and the reaction was allowed to proceed for 3 h or was left over night (approximately 18 h). For small-scale (~2 mg) cross-linking reactions, the reaction mixture was diluted 1 :1 with 0.2 % TFA/40 % CH3CN/6O % H ₂ O, filtered and purified by RP-HPLC. For larger scale crosslinking reactions (10- 20 mg), the buffer was changed to 25 mM ammonium acetate (Merck) pH 6 using PD-10 columns (GE Healthcare), and the product was lyophilized, dissolved in 0.1 % TFA/20 % CH3CN/8O % H ₂ O and purified using semi- preparative RP-HPLC (Zorbax 300SB-C18, 9.4 250 mm, 5 μηη particle size, Agilent Technologies) on a 1200 series instrument (Agilent Technologies) and analyzed by LC-ESI-MS.

Crosslinkinq via Cvs-Cvs: The crosslinking of PEP14788 and PEP14789 was performed by mixing the protein sample with a crosslinker pre-dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich) in PBS (pH 7.4) supplemented with 10 mM EDTA to a concentration of 3 mg ml ^"1 . The following crosslinkers were used: A: o-xylylene dibromide (Alfa Aesar); B: m-xylylene dibromide (Merck); C: p-xylylene dibromide (Alfa Aesar); D: 2,3-bis(bromomethyl)- quinoxaline (Aldrich); and E: 2,6-bis(bromomethyl)pyridine (Aldrich). The pH was set to 8 by careful addition of 0.1 M NaOH. A 20-fold molar excess of the crosslinker was used to drive the reaction. The reaction was allowed to proceed for 2-3 h before the buffer was exchanged, and the protein lyophilized and purified as described above. After purification, the pure, crossl inked proteins were lyophilized. Results

Crosslinking via Lvs-Cvs: The crosslinking reaction was performed by dissolving the protein in buffer under conditions where the protein is folded and the thiol group of the cysteine residue can form a nucleophilic attack on the a-carbon of the chloroacetyl group forming a thioether bond:

The crosslinking reaction was very efficient and clean for PEP18049, PEP18050 and PEP18051 , which all contain one functionalized lysine. The clean reaction makes it possible to use crude and unpurified polypeptides in the reaction and obtain a pure crosslinked product in relatively high synthetic yield (such as a yield of 10-17 % based on the HPLC elution profile at 220 nm). The crosslinking of PEP18052 and PEP18053, which both have two functionalized lysines, proved to be more complex. The expected MW of the double crosslinked protein was found in two separate peaks, which in later analysis showed the same behavior.

Crosslinking via Cvs-Cvs: The crosslinking of PEP14788 (which was produced chemically) and PEP14789 (which was produced recombinantly) was performed using a 20-fold excess of Crosslin ker to drive the reaction. Once one of the thiols has formed a covalent bond to the crosslinker, the second thiol should be in close contact as long as the polypeptide is correctly folded, and rapidly form the second covalent bond to the crosslinker. The reaction was very clean using the crosslinkers A (o-xylylene dibromide), B (m- xylylene dibromide) and E (2,6-bis(bromomethyl)pyridine), and no purification of the synthetic polypeptide was needed before crosslinking. The major byproduct was the disulfide crosslinked protein, which could be completely removed by adding a reducing agent to the crosslinking buffer. Reactions using the crosslinkers C (p-xylylene dibromide) and D (2,3-bis(bromomethyl)- quinoxaline) were less efficient and polypeptides including these linkers were not analyzed further. The Cys-Cys crosslinked variants are herein referred to as PEP14788_CL_X and PEP14789_CL_X where X specifies linker A, B or E.

Example 3

Circular dicroism spectroscopy analysis In this Example, circular dicroism (CD) spectroscopy was used to analyze the secondary structure of the chemically synthesized and

crosslinked polypeptides produced as described in Example 1 and 2.

Additionally, where it was possible, the melting temperatures (Tm) of said polypeptides were determined.

Materials and methods

Polypeptides were dissolved in PBS (pH 7.4) to a concentration of 50 μΜ (approximately 0.25 mg ml ^"1 ) and CD spectra and melting curves were collected on a Jasco J-810 spectropolarimeter (Jasco) using a cell with an optical path-length of 1 mm. Variable temperature measurements, VTM, were used to determine Tm. In these measurements, the absorbance was measured at 221 nm from 20 °C to 90 °C, with a temperature slope of 5 °C min ^"1 . The secondary structure of each variant was analyzed by recording a spectrum ranging from 250 to 195 nm at 20 °C, both before and after VTM.

Results

The CD spectra of PEP18049_CL and the reference protein PEP07830 have local minima at 208 nm and 221 nm, as is typical for alpha helical proteins (Figure 4A and 4B). PEP14788_CL_A, PEP14788_CL_B and PEP14788_CL_E also display these typical CD spectra. The four other crosslinked variants did not show these characteristic spectra, indicating that the a-helical secondary structure was partly or completely lost in these molecules.

VTMs were collected for all polypeptide versions using the CD signal at 221 nm. The melting profiles of PEP18049_CL and the reference protein PEP07830 show a clear transition, indicating a cooperative unfolding of the protein characteristic of a well folded protein (Figure 4C). The melting temperatures were calculated by determining the midpoint of the transition in the CD versus temperature plot. PEP18049_CL exhibited a Tm of 63 °C, corresponding to an increase of approximately 5 °C compared to the Tm of PEP07830, and indicating a more stable protein. The melting profiles of PEP14788_CL_A, PEP14788_CL_B and PEP14788_CL_E showed a lower Tm compared to the reference protein PEP07830 (Table 3). The melting temperatures for the less structured crosslinked variants could not be determined.

SEQ ID NO Polypeptide Tm of linear polypeptide variant (°C)

1774 PEP07830 58

1 PEP18049_CL 63

3 PEP14788_CL_A -55

3 PEP14788_CL_B -51

3 PEP14788_CL_E -45

Table 2: Melting temperatures of crosslinked and reference polypeptides. Example 4

Albumin binding analysis

This Example describes the analysis of the albumin binding ability of chemically synthesized, as well as recombinantly expressed, crosslinked polypeptides produced as described in Examples 1 and 2.

Materials and methods

Biosensor binding analyses were performed on a ProteOn XPR36 instrument (Bio-Rad) at 25 °C using PBST (150 mM NaCI, 8 mM Na ₂ HPO ₄ , 2 mM NaH ₂ PO , 0.005 % Tween20, pH 7.4) as running buffer at a flow rate of 50 μΙ min ^"1 . An injection of 30 μΙ of 20 mM HCI at a flow rate of 100 μΙ min ^"1 was used for chip regeneration. In a screening experiment, the binding of all polypeptide variants to human serum albumin (HSA) was investigated. The proteins were diluted to 50 nM in running buffer and injected over a chip surface with 2500 RU of immobilized HSA. The association was studied for 300 s and the dissociation was followed for 7200 s (2 h). For data analysis, all samples were double referenced; the signal from a blank surface was first subtracted from the signal from the respective protein, and secondly the signal from an injection of PBST (running buffer) over the HSA surface was subtracted.

The HSA binding kinetics of PEP18049_CL and the reference protein PEP07830 were further studied using a sensor chip with HSA immobilized on three different surfaces to between 1 100 RU and 1600 RU. The proteins were diluted in running buffer (0.8, 1 .6, 3.3, and 6.6 nM for PEP18049_CL and 1 .0, 2.0, 4.0 and 8.0 nM for PEP07830) and injected over the three HSA surfaces and thus giving binding curves in triplicate. The association time was 300 s and the dissociation was followed for 36 000 s (10 h).

The kinetic parameters of the binding of PEP18049_CL and the reference protein PEP07830 to HSA were obtained from fitting the obtained sensorgrams to a 1 :1 Langmuir binding model using the ProteOn Manager software version 3.1 .0.6 (Bio-Rad). The average association rate constant (k _a (M ^"1 s ^"1 ) and dissociation rate constant (k _d (s ^"1 )) with standard deviation were calculated. From the average k _a and the k _d the dissociation equilibrium constant (K _D (M)) was calculated (K _D = k _d /k _a ). Results

HSA binding of the crosslinked polypeptide variants and of the reference protein PEP07830 was analyzed in real time by SPR-based biosensor

(ProteOn) experiments. The first screening experiment showed that

5 PEP18049_CL had a fast on-rate and a two phase-like dissociation: a fast

and immediate dissociation followed by a much slower dissociation after

approximately 30 min (Figure 5A). PEP18050_CL and PEP18052_CL had completely lost their affinity for HSA, while PEP18053_CL still displayed weak binding. PEP18051_CL showed a slower on-rate, but also seemed to have a 0 very slow off-rate indicating a high affinity for HSA.

In a second screening experiment, the HSA binding of the chemically synthesized PEP14788_CL_A, PEP14788_CL _B, and PEP14788_CL _E were compared to PEP18049_CL (Figure 5B). All three Cyc-Cys coupled variants showed similar binding affinities for HSA, comparable to

5 PEP18049_CL.

In a third screening experiment, the HSA binding of the recombinantly produced PEP14789_CL_A and PEP14789_CL_B were compared to

PEP18049_CL (Figure 5C). These two variants also showed similar binding affinities for HSA, comparable to PEP18049_CL.

0 The HSA binding of PEP18049_CL and the reference polypeptide

PEP07830 was studied in more detail, but due to extremely slow off-rates it was not possible to use a ProteOn XPR36 for determination of the exact kinetic parameters, including K _D values. Thus, the calculated K _D values (Table 3) can only be used for comparison in this series of experiments. The

5 biosensor experiments were done in triplicates and demonstrated that

crosslinked PEP18049_CL binds HSA with a very high affinity (K _D * 24 pM), which affinity does not differ significantly from the affinity of the linear

reference polypeptide PEP07830 (K _D * 21 pM).

SEQ ID NO

Polypeptide

of linear k _a k _d K _D variant

polypeptide (MV ¹ ) is ^"1 ) (M)

1 PEP18049_CL 6.2(±0.7) x 10 ⁵ 1.5(±0.1 ) x 10 ^"5 24 x 10 ^"12

1774 PEP07830 1.9(±0.5) x 10 ⁵ 4.1 (±1.1 ) x 10 ^"6 21 x 10 ^"12 0 Table 4: Relative kinetic parameters for binding of polypeptides to HSA. Example 5

Protease degradation analysis

In this Example, the resistance of tested polypeptides to proteolytic cleavage by pepsin alone and by a combination of trypsin and chymotrypsin was analyzed.

Materials and methods

Proteolytic degradation was studied using pepsin (obtained from porcine gastric mucosa, 3200-4500 U mg ^"1 , Sigma) and a mixture of trypsin (obtained from bovine pancreas, =37 U mg ^"1 , Sigma) and chymotrypsin (obtained from bovine pancreas, >40 U mg ^"1 , Sigma). In all degradation experiments, 5 g protein in PBS (pH 7.4) at a concentration of 0.25 mg ml ^"1 (50 μΜ) was used.

Treatment with pepsin: 5 g of each variant was transferred to a microcentrifuge tube. 32 μΙ 10 mM HCI with pepsin at a concentration of 3.25 g ml ^"1 or 0.81 g ml ^"1 , resulting in a pH around 2.6 and a final pepsin concentration of 2 g ml ^"1 to be used for screening experiment and 0.5 g ml ^"1 for studying the degradation over time. In the screening experiment, the samples were incubated for 10 min at 37 °C before the enzyme was inactivated by addition of 5 μΙ 0.1 M NaOH, which raised the pH to above 9, and then the sample was put on ice. A reference sample of each protein was inactivated with NaOH before pepsin was added to the tube.

The degradation over time was monitored for PEP18049_CL,

PEP14788_CL_A and the reference polypeptide PEP07830 by incubation for 3, 6, 12, 30 or 60 min at 37 °C before inactivation with NaOH. Reference samples, inactivated with NaOH before the pepsin was added to the tube, were incubated likewise.

Treatment with trypsin and chymotrypsin: 5 g of each variant was transferred to a microcentrifuge tube. 32 μΙ PBS (pH 7.4) with trypsin at a concentration of 4.39 g ml ^"1 and chymotrypsin at a concentration of 1 .95 g ml ^"1 was added to yield a final concentration of 2.7 g ml ^"1 of trypsin and 1 .2 g ml ^"1 of chymotrypsin. In the screening experiment, the samples were incubated for 10 min at 37 °C before the enzyme was inactivated by addition of 3 μΙ 10 % TFA and then the sample was put on ice. A reference sample of each protein was inactivated with TFA before the trypsin and chymotrypsin were added to the tube. The degradation over time was monitored for PEP18049_CL,

PEP14788_CL_A and the reference polypeptide PEP07830 by incubation for 3, 6, 12, 30, or 60 min at 37 °C before inactivation with TFA. As above, reference samples, inactivated with TFA before trypsin and chymotrypsin were added to the tube, were incubated likewise.

All samples were analyzed by RP-HPLC using an analytical column (Zorbax 300SB-C18, 4.6 χ 150 mm, 3.5 μηη particle size, Agilent

Technologies) and a gradient of 15-45 % solvent B (solvent A: 0.1 % TFA- H ₂ O; solvent B: 0.1 % TFA-CH ₃ CN) over 25 min at a flow rate of 1 .2 ml min ^"1 and LC-ESI-MS on a 6520 Accurate Mass Q-TOF LC/MS.

The elution peaks containing the intact polypeptides were integrated and the area under curve was calculated. The degradation experiments over time were performed in triplicates. The integrated area of each sample was normalized to the mean area of the t=0 samples of that variant, the mean and standard error of the mean were calculated for each time point.

To quantify the stability improvement of the crosslinked variants, the AUC (area under curve) from the normalized charts was calculated for the three investigated variants. The AUC of the crosslinked variants was then compared to the AUC of the reference polypeptide.

Results

The first screening experiments clearly demonstrated that

PEP18049_CL has an increased resistance towards degradation by both pepsin and the combination of trypsin and chymotrypsin compared to the reference polypeptide. None of the other crosslinked variants showed improved protease stability under the experimental conditions used. In the second screening experiments, the protease stability of PEP14788_CL_A, PEP14788_CL_B, and PEP14788_CL_E was compared. This experiment showed that there was no significant difference between these variants.

The protease stability of PEP18049_CL, PEP14788_CL_A and the reference polypeptide PEP07830 was studied in further detail and the degradation of the proteins was followed over time. These experiments clearly show that the protease stability of PEP18049_CL compared to the reference protein is significantly improved, in particular the resistance towards degradation by pepsin. A comparison of the area under the curve (AUC) for PEP18049_CL and the reference polypeptide PEP07830 shows that the total amount of full-length protein present during the 60 minutes is at least 17 times (1714 %) higher for PEP18049_CL than for PEP07830 when challenged with pepsin and almost 5 (482 %) times higher when challenged with trypsin and chymotrypsin (Figure 6). Also PEP14788_CL_A showed improved stability as compared to PEP07830 as the AUC increased 2.4-fold and 1 .4-fold for the pepsin and the combination trypsin and chymotrypsin, respectively.

Investigation of the major degradation products from pepsin degradation of the reference polypeptide PEP07830 showed that the peptide bond between Leu42 and Ala43 is rapidly cleaved, and that this C-terminally truncated protein is the dominating fragment after three minutes of incubation. This 43-residue fragment is then cleaved between Phe20 and Tyr21 giving rise to two new fragments, which are 21 and 22 amino acids long. When PEP07830 was challenged with the combination of trypsin and chymotrypsin, it was shown that the peptide bond between Tyr21 and Lys22 is the most susceptible for cleavage. In addition to cleavage at this position, several peptide fragments formed by cleavage after arginine or lysine residues could be detected. These degradation patterns are in line with the known fact that pepsin preferentially cleaves at Phe, Tyr, Trp and Leu in position P1 or P1 ', while chymotrypsin preferentially cleaves at Trp, Tyr and Phe in position P1 and trypsin at Arg or Lys at position P1 .

To summarize, the crosslinked PEP18049_CL surprisingly showed a dramatic increase in its resistance towards degradation by pepsin (17-fold) and by trypsin together with chymotrypsin (5-fold) compared to the reference polypeptide PEP07830. PEP18049_CL displayed a Tm which was 5 °C higher than that of PEP07830, and an affinity for HSA within the same range, with a K _D value in the low picomolar range (24 pM). A variant of PEP18049 with two cysteines crosslinked with a dihalides (PEP14788_CL_A), which allows for recombinant production (as exemplified herein by PEP14789_CL), showed a high affinity for HSA and an improved resistance towards

degradation by pepsin (2.4-fold) and by trypsin together with chymotrypsin (1 .4-fold) compared to PEP07830. ITEMIZED LISTING OF EMBODIMENTS

1 . Albumin binding polypeptide comprising an albumin binding motif [ABM], which motif consists of the amino acid sequence

GXASDXsYKXeXgl Xl iXi2AX-| ₄ TVEGVX20 ALX23X2 ₄ X2SI LX28X29XB wherein, independently from each other,

XA is selected from C and K;

XB is selected from C and K; and

X ₅ is selected from F and Y;

Xs is selected from D, K, N, R and S;

X9 is selected from F, I, L, M, V and Y;

X11 is selected from D, E, N and S;

X12 is selected from K, N and R;

Xi ₄ is selected from K and R;

X ₂₀ is selected from D, E, H, K, N, Q, R and S;

X23 is selected from I, K and T;

X2 ₄ is selected from A, D, E, G, H, L, S and T;

X25 is selected from A, D, E and H;

X28 is selected from A and K; and

X29 is selected from A, E and S.

2. Albumin binding polypeptide according to item 1 , wherein X _A is C.

3. Albumin binding polypeptide according to item 1 , wherein X _A is K.

4. Albumin binding polypeptide according to any preceding item, wherein X _B is C.

5. Albumin binding polypeptide according to any one of items 1 -2, wherein X _B is K.

6. Albumin binding polypeptide according to any one of items 2 and 5, wherein X _A XB is CK.

7. Albumin binding polypeptide according to any one of items 2 and 4, wherein X _A XB is CC. 8. Albumin binding polypeptide according to any one of items 3 and 4, wherein X _A XB is KC.

9. Albumin binding polypeptide according to any one of items 3 and 5, wherein X _A XB is KK.

10. Albumin binding polypeptide according to any preceding item, wherein X ₅ is F.

1 1 .Albumin binding polypeptide according to any one of items 1 -9, wherein X ₅ is Y.

12. Albumin binding polypeptide according to any preceding item, wherein X ₈ is selected from K, N, R and S.

13. Albumin binding polypeptide according to item 12, wherein X ₈ is selected from N, R and S.

14. Albumin binding polypeptide according to item 12, wherein X ₈ is selected from K, N and R.

15. Albumin binding polypeptide according to item 13 or 14, wherein X ₈ is selected from N and R.

16. Albumin binding polypeptide according to item 14, wherein X ₈ is selected from K and R.

17. Albumin binding polypeptide according to item 15 or 16, wherein X ₈ is R.

18. Albumin binding polypeptide according to item 15 wherein X ₈ is N.

19. Albumin binding polypeptide according to item 16, wherein X ₈ is K.

20. Albumin binding polypeptide according to any preceding item, wherein X ₉ is L.

21 .Albumin binding polypeptide according to any preceding item, wherein X is selected from D, E and N.

22. Albumin binding polypeptide according to any one of items 1 -20, wherein X is selected from N and S.

23. Albumin binding polypeptide according to item 21 or 22, wherein X is N.

24. Albumin binding polypeptide according to item 21 , wherein X is selected from D and E.

25. Albumin binding polypeptide according to item 24, wherein X is D.

26. Albumin binding polypeptide according to item 24, wherein Xn is E. 27. Albumin binding polypeptide according to any preceding item, wherein Xi ₂ is selected from K and N. 28. Albumin binding polypeptide according to any one of items 1 -26, wherein Xi ₂ is selected from K and R.

29. Albumin binding polypeptide according to item 27 or 28, wherein Xi ₂ is K.

30. Albumin binding polypeptide according to item 27, wherein Xi ₂ is N.

31 .Albumin binding polypeptide according to item 28, wherein Xi ₂ is R.

32. Albumin binding polypeptide according to any preceding item, wherein Xi is K.

33. Albumin binding polypeptide according to any preceding item, wherein X ₂₀ is selected from D, E, H, N, Q, R and S.

34. Albumin binding polypeptide according to any one of item 1 -32, wherein X ₂₀ is selected from K and E.

35. Albumin binding polypeptide according to item 33 or 34, wherein X ₂₀ is E.

36. Albumin binding polypeptide according to item 34, wherein X ₂₀ is K.

37. Albumin binding polypeptide according to any preceding item, wherein X ₂₃ is selected from I and K.

38. Albumin binding polypeptide according to item 37, wherein X ₂₃ is I.

39. Albumin binding polypeptide according to item 37, wherein X ₂₃ is K. 40. Albumin binding polypeptide according to any preceding item, wherein X ₂ is selected from A, D, G, H, L, S and T.

41 .Albumin binding polypeptide according to any one of items 1 -39, wherein X ₂ is selected from A, E, G, H, L, S and T.

42. Albumin binding polypeptide according to item 40 or 41 , wherein X ₂ is selected from A, G, H, L, S and T.

43. Albumin binding polypeptide according to any one of items 1 -39, wherein X ₂ is selected from D, E and L, such as selected from D and E.

44. Albumin binding polypeptide according to any one of items 42 and 43, wherein X ₂ is L.

45. Albumin binding polypeptide according to any one of items 40 and

43, wherein X ₂ is D.

46. Albumin binding polypeptide according to any one of items 41 and 43, wherein X ₂ is E.

47. Albumin binding polypeptide according to any preceding item, wherein X ₂₅ is selected from A, E and H, such as selected from A and H or selected from A and E. 48. Albumin binding polypeptide according to any one of items 1 -46, wherein X ₂₅ is selected from D, E and H.

49. Albumin binding polypeptide according to item 48, wherein X ₂₅ is selected from D and E.

50. Albumin binding polypeptide according to item 47 or 49, wherein X ₂₅ is E.

51 .Albumin binding polypeptide according to item 47, wherein X ₂ 5 is A.

52. Albumin binding polypeptide according to item 49, wherein X ₂₅ is D.

53. Albumin binding polypeptide according to item 47 or 48, wherein X ₂₅ is H.

54. Albumin binding polypeptide according to any preceding item, wherein X ₂₈ is A.

55. Albumin binding polypeptide according to any preceding item, wherein X ₂₉ is selected from A and S.

56. Albumin binding polypeptide according to item 55, wherein X ₂₉ is A.

57. Albumin binding polypeptide according to item 55, wherein X ₂₉ is S.

58. Albumin binding polypeptide according to any preceding item, wherein said albumin binding motif [ABM] comprises an additional position X31 located on the C-terminal side of the ABM.

59. Albumin binding polypeptide according to item 58, wherein X31 is P.

60. Albumin binding polypeptide according to any preceding item, in which the [ABM] consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1 -1768.

61 .Albumin binding polypeptide according to item 60, in which the [ABM] consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1 -4.

62. Albumin binding polypeptide according to item 61 , in which the [ABM] consists of an amino acid sequence extending from position 16 to position 45 in an amino acid sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:3.

63. Albumin binding polypeptide according to item 62, in which the [ABM] consists of an amino acid sequence extending from position 16 to position 45 in SEQ ID NO:1 . 64. Albumin binding polypeptide according to any preceding item, in which said albumin binding motif forms part of a three-helix bundle protein domain.

65. Albumin binding polypeptide according to item 64, in which said three-helix bundle protein domain is selected from the group consisting of three-helix domains of bacterial receptor proteins.

66. Albumin binding polypeptide according to claim 65, in which said bacterial receptor protein is selected from the group consisting of albumin binding receptor proteins from species of Streptococcus, Peptostreptococcus and Finegoldia.

67. Albumin binding polypeptide according to claim 66, in which said albumin binding receptor protein is selected from the group consisting of G, MAG, ZAG, PPL and PAB.

68. Albumin binding polypeptide according to claim 67, in which said albumin binding receptor protein is protein G.

69. Albumin binding polypeptide according to claim 68, in which said albumin binding receptor protein is protein G from Streptococcus strain G148.

70. Albumin binding polypeptide according to claim 69, in which said three-helix bundle protein domain is selected from the group consisting of domain GA1 , domain GA2 and domain GA3 of protein G from Streptococcus strain G148, in particular domain GA3 of protein G from Streptococcus strain G148.

71 .Albumin binding polypeptide according to claim 65, in which said bacterial receptor protein is protein A from Staphylococcus aureus.

72. Albumin binding polypeptide according to claim 71 , in which said three-helix bundle protein domain is selected from the group consisting of protein A domains A, B, C, D and E.

73. Albumin binding polypeptide according to claim 71 , in which said three-helix bundle protein domain is protein Z derived from domain B of protein A from Staphylococcus aureus.

74. Albumin binding polypeptide according to item 64, which comprises the amino acid sequence:

LAXaAKXbXcAXdXe ELX _f X _g Y-[ABM]

wherein

[ABM] is an albumin binding motif as defined by any one of items 1 -63, and, independently of each other,

X _a is selected from C, E, Q and S; Xb is selected from C, E, S and V;

Xc is selected from A, D, E, L and S;

Xd is selected from I, N and L;

X _e is selected from A, K, R and S;

X _f is selected from D and K; and

X _g is selected from A, C, K and S.

75. Albumin binding polypeptide according to item 74, wherein X _a is selected from S and E.

76. Albumin binding polypeptide according to item 75, wherein X _a is S.

77. Albumin binding polypeptide according to item 75, wherein X _a is E.

78. Albumin binding polypeptide according to any one of items 74-77, wherein X _b is selected from C, E and S or alternatively selected from E and V.

79. Albumin binding polypeptide according to item 78, wherein X _b is E. 80. Albumin binding polypeptide according to item 78, wherein X _b is V.

81 .Albumin binding polypeptide according to any one of items 74-80, wherein X _c is selected from A and L.

82. Albumin binding polypeptide according to any one of items 74-80, wherein X _c is selected from A and S.

83. Albumin binding polypeptide according to item 81 or 82, wherein X _c is A.

84. Albumin binding polypeptide according to item 81 , wherein X _c is L.

85. Albumin binding polypeptide according to any one of items 74-84, wherein X _d is N.

86. Albumin binding polypeptide according to any one of items 74-85, wherein X _e is selected from A and R.

87. Albumin binding polypeptide according to any one of items 74-85, wherein X _e is selected from A and S.

88. Albumin binding polypeptide according to item 86 or 87, wherein X _e is A.

89. Albumin binding polypeptide according to item 86, wherein X _e is R.

90. Albumin binding polypeptide according to item 87, wherein X _e is S. 91 .Albumin binding polypeptide according to any one of items 74-90, wherein X _f is D.

92. Albumin binding polypeptide according to any one of items 74-91 , wherein X _g is selected from C, K and S. 93. Albumin binding polypeptide according to item 92, wherein X _g is selected from K and S.

94. Albumin binding polypeptide according to item 92, wherein X _g is selected from C and S.

95. Albumin binding polypeptide according to item 93 or 94, wherein X _g is S.

96. Albumin binding polypeptide according to item 93, wherein X _g is K.

97. Albumin binding polypeptide according to item 94, wherein X _g is C.

98. Albumin binding polypeptide according to any one of the preceding items, which comprises an amino acid sequence selected from SEQ ID NO:1 -

1768.

99. Albumin binding polypeptide according to any one of the preceding items, which comprises an amino acid sequence selected from SEQ ID NO:1 - 4.

100. Albumin binding polypeptide according to any one of the preceding items, which comprises an amino acid sequence selected from

SEQ ID NO:1 and SEQ ID NO:3.

101 . Albumin binding polypeptide according to any one of the preceding items, which comprises the amino acid sequence SEQ ID NO:1 .

102. Albumin binding polypeptide according to any one of items 1 -6 and 8-101 , wherein said K in position X _A or X _B , when present, is

functionalized.

103. Albumin binding polypeptide according to item 102, wherein said functionalized K comprises a haloacetyl group, such as a chloroacetyl group.

104. Albumin binding polypeptide according to any preceding item, wherein said amino acid sequence is crosslinked.

105. Albumin binding polypeptide according to item 104, wherein said crosslink extends between the amino acid residue in position X _A and the amino acid residue in position X _B of said amino acid sequence.

106. Albumin binding polypeptide according to any one of items 104-

105, wherein said crosslink is selected from the group comprising

- thioether bond between a haloacetylated lysine residue and a thiol group of a cysteine residue or thiol-modified lysine residue,

- thioether bond between a maleimide-functionalized lysine residue and a thiol group of a cysteine residue or thiol-modified lysine residue,

- thioether bond between a pyridyld ith iol-functional ized lysine residue and a thiol group of a cysteine residue or thiol-modified lysine residue, - thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional dihalogenated linker,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional dimaleimide linker,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional dipyridyldithiol linker,

- thioether bond between the thiol groups of cysteine residues or thiol- modified lysine residues and a bifunctional perfluoroaromatic linker,

- disulfide bond between the thiol groups of cysteine residues or thiol- modified lysine residues,

- oxime bond between an aminooxy-modified amino acid residue and an aldehyde-modified amino acid residue,

- oxime bond between an aminooxy-modified amino acid residue and a ketone-modified amino acid residue,

- bond formed by Cu-catalyzed cycloaddition between an azido-modified amino acid residue and an alkyne-modified amino acid residue,

- bond formed by Staudinger reaction between an azido-modified amino acid residue and a triarylphosphine-modified amino acid residue, and

- bond formed by native chemical ligation reaction between a thioester- modified amino acid residue and a cysteine-modified amino acid residue.

107. Albumin binding polypeptide according to any one of items 104- 106, wherein said crosslink is a thioether bond.

108. Albumin binding polypeptide according to claim 107, wherein said crosslink is a thioether bond between a haloacetylated lysine residue and the thiol group of a cysteine residue, such as a thioether bond between a chloroacetylated lysine residue and the thiol group of a cysteine residue.

109. Albumin binding polypeptide according to any one of items 104- 106, wherein said crosslink is a disulfide bond.

1 10. Albumin binding polypeptide according to item 109, wherein said crosslink is a disulfide bond between the thiol groups of two cysteine residues.

1 1 1 . Albumin binding polypeptide according to item 1 10, wherein said disulfide bond is obtained by using a dihalide crosslinker.

1 12. Albumin binding polypeptide according to item 1 1 1 , wherein said crosslinker is selected from the group consisting of o-xylylene dibromide, m- xylylene dibromide, p-xylylene dibromide, 2,3-bis(bromomethyl)quinoxaline and 2,6-bis(bromomethyl)pyridine. 1 13. Albumin binding polypeptide according to item 1 12, wherein said crosslinker is selected from the group consisting of o-xylylene dibromide, m- xylylene dibromide and 2,6-bis(bromomethyl)pyridine.

1 14. Albumin binding polypeptide according to any one of items 104- 1 13, wherein said albumin binding motif retains a two alpha helix

conformation.

1 15. Albumin binding polypeptide according to any one of items 104-

1 14, wherein said albumin binding polypeptide retains a three-helix bundle conformation.

1 16. Albumin binding polypeptide according to any one of items 104-

1 15, wherein said polypeptide is resistant to proteolytic cleavage.

1 17. Albumin binding polypeptide according to item 1 16, wherein said proteolytic cleavage is by at least one protease of the gastrointestinal tract.

1 18. Albumin binding polypeptide according to item 1 17, wherein said at least one protease is selected from pepsin, trypsin, chymotrypsin and combinations thereof.

1 19. Albumin binding polypeptide according to item 1 17, wherein said at least one protease is pepsin.

120. Albumin binding polypeptide according to item 1 17, wherein said at least one protease is trypsin.

121 . Albumin binding polypeptide according to item 1 17, wherein said at least one protease is chymotrypsin.

122. Albumin binding polypeptide according to any one of items 104- 121 , which exhibits a melting temperature (Tm) of at least 37 °C, for example at least 39 °C, for example at least 41 °C, for example at least 43 °C, for example at least 45 °C, for example at least 47 °C, for example at least 49 °C, for example at least 51 °C, for example at least 53 °C, for example at least 55 °C, for example at least 57 °C, for example at least 59 °C, for example at least 61 °C, for example at least 63 °C, for example at least 65 °C, for example at least 67 °C, for example at least 69 °C, for example at least 71 °C, for example at least 73 °C, for example at least 75 °C.

123. Albumin binding polypeptide according to any preceding item, which binds to albumin such that the K _D value of the interaction is at most

1 x 10 ^"8 M, such as at most 1 x 10 ^"9 M, such as at most 1 x 10 ^"10 M, such as at most 1 x 10 ^{"1 1} M, such as at most 1 x 10 ^"12 M.

124. Albumin binding polypeptide according to any preceding item, wherein said albumin is human serum albumin. 125. Compound comprising:

- at least one moiety (I) which is an albumin binding polypeptide

according to any one of the preceding items;

- one moiety (II) which confers a desired therapeutic activity; and

- optionally, at least one further moiety (III) which confers a desired

therapeutic activity, which activity may be the same or different from said activity of moiety (II).

126. Compound according to item 125, in which moiety (II) and/or at least one further moiety (III) comprise a component selected from the group consisting of human endogenous enzymes, hormones, growth factors, chemokines, cytokines, blood clotting and complement factors, innate immune defense and regulatory peptides, for example selected from the group consisting of insulin, insulin analogs, IL-2, IL-5, GLP-1 , BNP, IL 1 -RA, KGF, Stemgen®, GH, G-CSF, CTLA-4, myostatin, Factor VII, Factor VIII and Factor IX, and derivatives of anyone thereof.

127. Compound according to any one of items 125-126, in which moiety (II) and/or at least one further moiety (III) comprise a non-human biologically active protein, selected from the group consisting of modulins, bacterial toxins, hormones, innate immune defense and regulatory peptides, enzymes and activating proteins.

128. Compound according to any one of items 125-127, in which moiety (II) and/or at least one further moiety (III) comprise a binding polypeptide capable of selective interaction with a target molecule.

129. Compound according to item 128, in which the binding polypeptide is selected from the group consisting of antibodies and fragments and domains thereof substantially retaining antibody binding activity;

microbodies, maxybodies, avimers and other small disulfide-bonded proteins; and binding proteins derived from a scaffold selected from the group consisting of staphylococcal protein A and domains thereof, other three helix domains, lipocalins, ankyrin repeat domains, cellulose binding domains, γ crystallines, green fluorescent protein, human cytotoxic T lymphocyte- associated antigen 4, protease inhibitors such as Kunitz domains, PDZ domains, SH3 domains, peptide aptamers, staphylococcal nuclease, tendamistats, fibronectin type III domain, transferrin, zinc fingers and conotoxins.

130. Compound according to item 129, in which said binding polypeptide comprises a variant of protein Z derived from domain B of staphylococcal protein A, which variant comprises a scaffold amino acid sequence selected from SEQ ID NO:1775-1781 , wherein X denotes any amino acid residue.

131 . Compound according to any one of items 128-130, in which said target molecule is selected from the group consisting of tumor-related or other cell surface related antigens, such as CD14, CD19, CD20, CD22, CD30, CD33, CD37, CD40, CD52, CD56, CD70, CD138, cMet, HER1 , HER2, HER3, HER4, CAIX, CEA, IL-2 receptor, IGF1 R, VEGFR2, FcRn, MUC1 , PDGFR- beta, PSMA, TAG-72, FOLR1 , mesothelin, CA6, GPNMB, integrins and ephA2; cytokines such as TNF-a, IL-1 a, IL-1 β, IL-1 Ra, IL-5, IL-6, IL-13, IL- 17A, IL-18, IL-23, IL-36, G-CSF, GM-CSF, and their receptors; chemokines such as IL-8, CCL-2 and CCL1 1 , and their receptors; complement factors such as C3, C5 and factor D; growth factors such as HGF and myostatin; hormones such as GH, insulin and somatostatin; peptides such as Αβ peptide of Alzheimer's disease; other disease-associated amyloid peptides;

hypersensitivity mediators such as histamine and IgE, immunoglobulins such as IgG; blood clotting factors, such as von Willebrand factor; and toxins, such as bacterial toxins and snake venoms.

132. Compound according to item 125, in which moiety (II) and/or at least one further moiety (III) comprise a non-proteinaceous component selected from the group consisting of a) cytotoxic agents, for example calicheamycin, auristatin, doxorubicin, maytansinoid, taxane, ecteinascidin, geldanamycin, methotrexate, camptothecin, cyclophosphamide, cyclosporine and their derivatives, and combinations thereof; and b) anti-inflammatory agents, for example non-steroidal anti-inflammatory drugs, cytokine

suppressive anti-inflammatory drugs, corticosteroids, methotrexate, prednisone, cyclosporine, morroniside cinnamic acid, leflunomide and their derivatives, and combinations thereof.

133. Pharmaceutical composition, comprising a compound according to any one of items 125-132 and at least one pharmaceutically acceptable excipient.

134. Pharmaceutical composition according to item 133, which further comprises at least one component for increasing oral bioavailability of said therapeutic activity.

135. Pharmaceutical composition according to item 134, wherein said component is selected from the group consisting of protease inhibitors, absorbance enhancers, mucoadhesive polymers, formulation vehicles and any combination thereof.

136. Pharmaceutical composition according to any one of items 133-

135, which is present in a form selected from solid forms, such as pills, tablets, capsules, powders or granules; semi-solid forms, such as pastes; and liquid forms, such as elixirs, solutions or suspensions.

137. Pharmaceutical composition according to any one of items 133-

136, in a formulation designed for immediate, delayed or controlled release.

138. Pharmaceutical composition according to any one of items 133- 137, formulated as enteric-coated capsules.

139. Albumin binding polypeptide according to any one of items 1 - 124, compound according to any one of items 125-132 or pharmaceutical composition according to any one of items 133-138 for use in treatment.

140. Albumin binding polypeptide, compound or pharmaceutical composition for use according to claim 139, wherein said treatment is via oral administration.

141 . Albumin binding polypeptide, compound or pharmaceutical composition for use according to any one of claims 139 and 140, wherein said treatment is carried out according to a specified dosage regime.

142. Method of treatment of a mammalian subject in need of such treatment, comprising administration of a therapeutically effective amount of an albumin binding polypeptide according to any one of items 1 -124, compound according to any one of items 125-132 or pharmaceutical composition according to any one of items 133-138.

143. Method according to item 142, wherein said administration is oral administration.

144. Method according to any one of items 142-143, wherein said compound or pharmaceutical composition is carried out according to a specified dosage regime.